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The aim of this project was to demonstrate the presence of 
immune complexes (IC) in the sera of patients with Crohn's disease 
(CD). The integrity of the complement system (C) was also 
investigated and comparisons were made with similar investigations 
on patients with ankylosing spondylitis (AS) and rheumatoid 
arthritis (RA).
ICs were detected in the sera of 32.2% of patients with CD,
100% of sera from patients with AS and 55% of synovial fluids from 
patients with RA, as shown by assessment of anticomplementary 
activity (ACA). The method was believed to detect small ICs.
Although total haemolytic complement, as assessed by CH^^ assay, 
was normal both C3 and C4 levels were consistently elevated in the 
sera of patients with CD. All these factors were depressed in 
patients with AS and RA.
Measurement of C  activity and serum factors C3 and C4 gives a 
static picture of the involvement of C  in CD. A more dynamic 
view could be obtained by the demonstration of C3 inactivation 
products in the sera of patients with CD. This was demonstrated in 
32.9% of sera tested. This was taken as evidence of in vivo C  
activation by ICs and it was suggested that elevated C3 and C4 
levels were due to alterations in catabolism or synthesis.
No relationship was found between the presence of ICs and 
raised C  levels; these factors were not found to be related to 
duration of disease activity, steroid therapy or disease activity. 
Since no differences were observed between patients in active or 
quiescent phases of the disease, it was concluded that the disease 
is characterized by a continuing immunological process.
I X
Gel filtration and immunoglobulin analysis of ACA positive 
sera revealed that ACA was confined to high molecular weight 
fractions containing IgG and IgA. It was concluded that ICs in the 
sera of patients with CD were composed of IgG and possibly IgA 
complexed with an unknown antigen.
X
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C  Complement system
C Activated complement enzyme
C1-C9 Complement components 1-9
Cl-INH Cl inhibitory factor
Clq Complement component Clq
Clr Complement component Clr
Cls Complement component Cls
C3 Complement component C3
C3i C3 inactivation products
C4 Complement component C4
CD Crohn’s disease
CFT Complement fixation test
CHg^ Unit of C  causing 50% lysis of sheep red blood cells
cm centimeter
Con A Concanavalin A
°C Degrees Celsius
EDTA Ethylenediaminetetra-acetic acid
Factor B C3 Proactivator (C3 ProA), Glycine rich 3 glyco­
protein (GBG).
XI.
g Gravitational force. All rates of centrifugation are































SLE Systemic lupus erythematosus
SRBC Sheep red blood cells
TB Tuberculosis
T-cell Thymus-derived lymphocyte
t.d.s. Three times daily










1.1. DEFINITION AND DESCRIPTION OF CROHN'S DISEASE
Crohn's disease (CD) was first described by Crohn, Ginsburg 
and Oppenheimer (1932) as being distinct from other chronic 
inflammatory lesions of the bowel; CD had previously been confused 
with ulcerative colitis (UC), since they possess many common 
features, viz fever, diarrhoea and emaciation, leading eventually to 
obstruction of the small intestine. UC is usually confined to 
the colon. CD was originally thought to affect the terminal ileum 
only, but it has subsequently been confirmed that there may be 
involvement of all regions of the gastro-intestinal (GI) tract from 
the mouth to the anus. The colon is frequently affected. UC and CD 
are now distinguished by radiological examination after barium meal 
and by histological examination of biopsy specimens, though when 
CD is confined to the colon it can still be difficult to distinguish 
it from UC. CD may also manifest itself with extra-GI symptoms, such 
as uveitis, vasculitis, arthritis, liver disease and erythema nodosum, 
the significance of which will be discussed.
CD is then a chronic focal and frequently multiple inflammatory 
lesion of the alimentary tract, with a granulomatous histological 
appearance reminiscent of experimental delayed hypersensitivity at 
pathological sites.
The clinical features of the disease include ulceration of the 
mucosa accompanied by the typical transmural inflammation of the 
connective tissue. This process frequently leads to stenosis of 
the lumen of the intestine and the formation of locaUzed fistulae. 
Fistulae may occur between adjacent loops of intestine, to the vagina 
and also from the perianal region to the outside of the abdomen.
There may be a palpable mass, quite often in the right ileac fossa.
The chronic illness follows an unpredictable course, which varies 
with the individual, and consists of quiescent periods inter­
spersed with debilitating exacerbations when the disease is at 
its most active.
The symptoms of CD include colicky pain, diarrhoea, nausea, 
especially after eating, severe weight loss, anaemia and malab­
sorption syndromes depending on which part of the gut is affected.
Pathologically the mucosa and submucosa have a characteristic 
"cobble-stone" appearance with gross thickening of the bowel wall 
due to oedema, inflammation and fibrosis. "Skip" lesions may 
occur, separated by apparently normal sections of intestine. 
Radiography after barium meal shows constrictions where the lesions 
occur. The characteristic histological lesion, seen in about 60% 
of cases bears a strong resemblance to that seen in sarcoidosis 
(Blackburn, Hadfield and Hunt, 1939). Both diseases feature non- 
caseating granulomata with multinucleate Langhan's type giant cells. 
This feature also suggests a parallel with intestinal tuberculosis 
(TB) .
Some patients need no drug therapy and can be maintained on 
a careful diet, whereas others require high doses of steroids and 
immunosuppressants and eventually surgical resection of the 
diseased bowel. Drug treatment is essentially palliative, designed 
to control symptoms and avoid complications. Since the aetiology 
and pathogenesis of CD is largely unknown, specific treatment to 
effect a cure is not yet possible.
1.2.; AETIOLOGY AND PATHOGENESIS
In the past many suggestions as to the cause of CD have been 
proposed. No single factor alone has been indentified which can 
produce chronic CD and it may well be a clinical syndrome produced 
by a variety of agents (Kyle, 1972). The granulomata suggest a 
mycobacterial infection despite the absence of caseation (Jewell 
and Hodgson, 1976). Tubercular enteritis commonly affects the 
terminal ileum and remains important in the differential diagnosis 
of CD, especially in those parts of the world where TB is still 
prevalent. The distinction may not be straight-forward, but can 
usually be made on the presence of miliary tubercles in other parts 
of the body, the nature of the granulomata and the identification of 
acid-fast bacteria. TB responds to antibiotics, whereas although 
CD can be benefited by antibiotic therapy, it usually responds 
favourably to steroid treatment. Tubercle bacilli have not been 
cultured from Crohn's tissue. Nevertheless it has been suggested 
that CD may follow intestinal TB infection. Feilding (1970) proposed 
that when resistence to Mycobacterium tuberculesum is low exposure 
to the organism causes classical TB but when resistance to M. 
tuberculosum is moderate or high the mycobacterium may become 
modified and when attached to a hapten, such as bile salts, may 
become antigenic in a different way. CD has been likened to 
sarcoidosis (Mitchell and Rees, 1971, Willoughby and Mitchell, 1971; 
Richens et al, 1973), because of the similarity of the granulomatous 
lesion and it has been suggested that moderate resistance to 
M. tuberculosum results in sarcoidosis with the lungs being the 
target organ, and when resistance is high CD may arise with the 
resulting pathological disorder being in the intestine (Feilding, 
1970).
It has also been suggested that other bacteria may be 
involved (Jewell and Hodgson, 1976). M. paratuberculosis causes a 
chronic hyperplastic enteritis called Johne's disease in ruminants 
which most commonly affects the ileum, but other areas of the gut 
may be affected. A local reaction occurs whereby there is infil­
tration of lymphocytes and epithelioid cells but the mucosa does 
not become ulcerated and the bacilli are clearly seen in histological 
section. Despite the similarities, this organism has not been 
cultured from Crohn's tissue. Following reports that a typical 
mycobacterium infected with mycobacteriophages might be present in 
the tissues of patients with sarcoidosis, similar investigations 
were carried out on patients with CD but no such infection was 
demonstrated (Parent and Wilson, 1971).
Golde and McGill (1968) proposed that a mycobacterium, as yet 
unidentified, must be responsible for CD because of the efficacy 
of sulphonamides in some cases of CD.
Bacterial toxins produced in the lumen of the intestine have 
also been suggested to play a part in the aetiology of CD. Bacteria 
may interfere with normal catabolism and absorbtion of substances 
from the intestine (Kyle, 1972).
1.3. A TRANSMISSIBLE AGENT IN CROHN'S DISEASE
A transmissible agent in CD was first proposed by Mitchell and 
Rees (1970) after they demonstrated that granulomata could be 
produced in the footpads of mice after innoculation with material 
from diseased ileum and lymph nodes from patients with CD. Since 
then there have been many reports indicating that injections of 
crude or coarsley filtered homogenates of Crohn's tissue are 
capable of causing granulomata in the footpads of mice (Mitchell 
and Rees, 1971; Taub et al, 1974; Mitchell and Rees, 1976; Taub 
et al, 1976; Mitchell, Rees and Goswami, 1976) and in the intestine 
of rabbits (Cave et al, 1973; Cave, Mitchell and Brooke, 1975; 
Donnelly, Delaney and Healy, 1977), though other workers have failed 
to confirm this (Bolton et al, 1973; Heatley et al, 1975).
Subsequent passage of granulomata from animal to animal (Mitchell 
and Rees, 1971; Cave, Mitchell and Brooke, 1975; Mitchell and Rees, 
1976; Mitchell, Rees and Goswami, 1976) and the fact that the 
original homogenates retained the ability to produced granulomata 
after passage through 0.2 y filters (Cave, Mitchell and Brooke,
1975; Mitchell and Rees, 1976; Mitchell, Rees and Goswami, 1976) 
indicated that the transmissible agent may be of viral origin.
Recent improved techniques have shown viruses in Crohn's tissue. 
Farmer ^  (1973) showed an increase in cytomegalovirus titres in 
UC and from one case of CD they isolated this virus. Aronson et a^ 
(1974) showed the presence of virus in Crohn's tissue and intestinal 
fluid of 10/18 patients by cytopathogenic effects in tissue culture. 
The significance of this in CD and other GI disorders remains 
controversial as similar effects have been seen in other diseases. 
However, particles with the properties of a picorna virus have been 
isolated and cultured from Crohn's tissue (Gitnick and Rosen, 1976; 
Gitnick et al, 1976; Geraint-James, 1978). Bacteria have been
identified in the submucosa of the intestine in patients witb CD, 
by electron microscopy (Aluwihare, 1971; Parent anti Mitchell, 1976). 
When the intestinal anatomy is altered by inflammation it is 
reasonable to expect viruses and bacteria to be present but whether 
they are of primary pathogenic importance remains to be seen. 
Epidemiological studies have failed to find evidence for time and 
space clustering in CD to support the concept of viral aetiology 
(Miller et al, 1976).
1,4, OTHER POSSIBLE CAUSES OF CROHN'S DISEASE (Kyle, 1972)
1. The earliest feature of CD is enlargement of regional 
lymph nodes and oedema leading to lymphatic obstruction. It 
has proved difficult to cause experimental ulceration by 
lymphatic blockage alone. (Reichert and Mathes, 1936; Sinaiko, 
1946). Kalima and Collan (1970) showed that lymphatic 
obstruction in rats produced à transmural inflammation, but 
there were no graulomas.
2. Ingested foreign material has unconvincingly been 
suggested to be causative in CD on the basis of animal 
experiments. Instilling sand or talcum powder in the 
ileum of dogs has produced a CD effect with inflammation and 
giant cells (Chess et al, 1950). Similarly, carageenan when 
fed to rats can produce an UC-like effect (Marcus and Watt, 
1969).
3. Heredity may be of some importance. Certain families 
show a tendency to develop inflammatory bowel disease, 
either CD of UC (Lennard-Jones, 1968).
4. Following trauma, antigenic material may be released 
into the circulation and since it is not normally present 
there it could initiate an immunological reaction (Edwards, 
1969).
5. Psychological factors may play a role once the disease 
has been established, as this is a depressing disease (Edwards, 
1969).
6. Cross reactivity and aetiological link with sarcoidosis, 
has been proposed (Phear, 1958, Williams, 1965; Mitchell and 
rees, 1971; Richens et al, 1973).
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7. Immunological responses are thought to be important 
in the aetiology of CD because of the benficial effects of 
immunosuppressants and corticosteroids (Willoughby et al, 1971)
1.5. IMMUNOPATHOLOGY OF CROHN'S DISEASE
There are large amounts of lymphoid tissue in the ileo-caecal 
region of the gut, such as the Peyer's patches and also in the mucosa, 
Clinical observations show that CD runs a chronic relapsing course, 
not unlike that of rheumatoid arthritis which is believed to be of 
immunological aetiology (Zvaiffler, 1974). Immunological memory 
is believed to be long and an abnormality of the immune response may 
account for the protracted history of CD. Various types of skin 
lesion may occur unpredictàbly. Erythema nodosum often occurs with 
CD and there may have been eczema earlier in life.
The humoral antibody (Ab) system seems to be unimpaired in C.D. 
Serum immunoglobulin G (IgG) appears to be normal but there may be 
elevated IgA levels, some of which is probably secretory IgA '
(Deodhar elt al, 1969; Perrett et al, 1971) . IgG turnover has been 
reported to be increased (Bendixen et al, 1968) and serum IgM levels 
are raised if abcesses are present (Jensen, 1970). The
ability to mount primary and secondary responses to the bacterio­
phage (j)xl74 is reported to be normal (Bucknal et al, 1975) .
There is however, much controversy over the integrity of the 
cellular immune response in inflammatory bowel disease. Depression 
of delayed hypersensitivity responses in the skin have been reported 
(Blackburn et al, 1939; Phear, 1958; Williams, 1965; Verrier-Jones 
et al, 1969) . Other workers have disputed this (Binder et al, 1966; 
Fletcher and Hinton, 1967; Bolton et al, 1974).
In vitro hyporesponsiveness in lymphocyte transformation in 
patients with CD is well documented (Parent et al, 1971; Sachar 
et al, 1973; Richens et al, 1974; Meuwissen et al, 1975; Hodgson, 
Wands and Isselbacher, 1978). Walker and Greaves (1969) and Brown
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et (1970) reported reduced lymphocyte transEormation in response 
to pokeweed mitogen (Brown et al, 1970). On this basis it was 
suggested that only certain populations of lymphocytes showed anergy. 
However, many other reports have shown normal lymphocyte transformation 
(Asquith et al, 1973; Ropke, 1972; Aas et al, 1972; Bolton et al,
1974; Bird and Britton, 1974). Corticosteroid therapy has been shown 
to reduce lymphocyte responsiveness to mitogens (Fauci and Dale, 1974; 
Ramer and Yu, 1978).
The discrepancies between various reports may in part be 
explained by the choice of controls and variations in methodology.
In general it appears that there is impairment of cellular immunity 
in CD.
Analysis of sub-populations in circulating white cells in 
inflammatory bowel disease again gives contradictory results. One 
report suggested a slight decrease in the percentage of T-cells with 
normal or increased percentage of B-cells (Strickland et al, 1974) 
whilst another demonstrated that although the percentage of all 
lymphocytes was reduced, probably due to an increase of polymor­
phonuclear (PMN) cell numbers, the actual numbers of T- and B-cells 
were normal, though erythrocyte-anti-body-complement: rosetting 
cells were reduced (Thayer et al, 1976).
Many studies have investigated the cell populations in the 
bowel mucosa in CD. This type of study is probably more relevant 
to the disease process. Overall increases in numbers of mucosal 
immunocytes have been reported (Strickland, 1975) in diseased areas 
of bowel sections from patients with CD. Strickland (1975) reports 
that increased numbers of B-lymphocytes are found in the lamina 
propria of diseased bowel and of these 60% are IgG staining.
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whereas in control sections of bowel similar numbers of T- and B- 
cellSwere found and of the B-cells 85% were IgA staining and only 
5% IgG staining. In the peripheral blood of patients with CD 
decreased numbers of T-cells were found (Strickland, 1975) 
suggesting a shift to the diseased intestine. Green and Pox (1975) 
also found a deficit of IgA containing plasma cells in diseased 
areas of bowel from patients with CD although overall numbers of 
plasma cells were increased in both involved and unaffected intestinal 
mucosa when compared to sections of bowel from control patients.
Since locally produced IgA plays a dominant role in the maintenance 
of a barrier to antigenic material, possibly by reducing Ag 
adhesiveness to mucosal cells or by forming non-absorbable stable 
complexes with Ag, this barrier will be reduced, the permeability 
of the intestinal epithelium to antigenic material will be increased 
and may even be accentuated by the epithelial binding of IgG which 
is believed to inhibit IgA activity and even increase uptake of 
antigen (Ag) (Green and Fox, 1975). Locally increased permeability 
to Ag offers an explanation of many of the pathological features of 
CD. Electron microscopy (Aluwihare, 1971) has demonstrated clusters 
of different bacteria deep in intact intestinal mucosa of patients 
with CD. This indicates that entry of antigenic material into the 
gut wall may not simply be secondary to ulceration.
In contrast, other workers have failed to find any significant 
difference in lymphocyte counts of lamina propria and intestinal 
epithelium in patients with CD or in control subjects (Bird and 
Britton, 1974; Ferguson, Allan and Cooke, 1975). In addition, 
disease activity, steroid therapy and anatomical localisation of 
the disease or resection did not have a significant affect on
12
lymphocyte counts. Plasma cell counts, however, were found to be 
raised as reported by Green and Fox (1975). Again, disease activity, 
drug therapy and anatomical involvement did not make a significant 
difference in plasma cell counts. Animal experiments indicate that 
the presence of plasma cells in the lamina propria is secondary to 
antigenic stimulation (Ferguson, Allan and Cooke, 1975). It has 
been suggested that increased numbers of plasma cells could be there 
in response to an abnormal Ag present in the proximal intestine or 
to a substance not normally antigenic (Ferguson, Allan and Cooke, 
1975).
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1.6. IMMUNE COMPLEXES AND CROHN'S DISEASE
A further possible factor in the aetiology and pathogenesis 
of CD may be the formation and circulation of immune complexes (IC) 
in this condition. There is evidence for the presence of ICs in 
the sera of patients with CD (Doe, Booth and Brown, 1973; Jewell 
and MacLennan, 1973; Hodgson, Potter and Jewell, 1977a and 1977c; 
Teisberg and Gjone, 1975). It has been suggested that circulating 
ICs may be responsible for the extra-GI manifestations of the disease 
such as arthritis, uveitis, vasculitis, liver disease and erythema 
nodosum.
Two biological events may occur following the formation of 
ICs. Firstly ^  vitro investigations have shown that ICs may both 
induce and inhibit lymphocyte toxicity depending on culture conditions 
(Perlmann, Perlmann and Wigzell, 1972). Secondly, ICs are also 
known to induce activation of the C  system (Mayer, 1973).
Activation of the C  system is relevant to the work described in this 
project.
1.6.1. THE COMPLEMENT SYSTEM
Briefly, the C  system consists of 11 serum proteins, denoted 
by C1-C9. The sequential interaction of the C  proteins results in 
a number of important biological consequences, most of which result 
from activation of the terminal components C3 to C9. Activation of 
C3 can be initiated by two discrete mechanism known as the "classical" 
and the "alternative" pathways.
The sequence of events that follows activation of C  by both 
























In the classical pathway, Clq is the recognition unit for the 
Fc portion of an Ab which becomes revealed or activated when it 
combines with its corresponding Ag. Only IgM and several sub­
classes of IgG are able to bind Cl in this way which results in its 
conversion to an active proteolytic enzyme with the active site 
being on the Cls sub-unit and the natural substrates being C4 
and 02. Activated Cls is capable of cleaving many molecules of 
C4, resulting in a shower of C4b molecules, some of which become 
bound to the cell surface and others which quickly become inactivated 
and circulate in the blood. C2 is then adsorbed onto the bound C4b 
and is cleaved by Cls into C2a and C2b. C2a becomes bound to C4b 
and the resulting enzyme C4b2a is capable of cleaving many molecules 
of C3 resulting in a shower of C3a and C3b molecules. C3a is 
released into the fluid phase and plays a role as a mediator of 
inflammation. C3b becomes bound to receptors on the cell surface.
A new enzyme is created, C4b2a3b, which is capable of cleaving C5 
and so the sequence proceeds. C3b bound to other sites on the cell 
surface is believed to play a role in promoting phagocytosis.
In the alternative pathway, a system of serum proteins termed 
properdin is involved, which acting together with C ,  participate in 
several immunological reactions, including promotion of phagocytosis 
of cells and foreign particles and the production of inflammatory 
reactions. Activation of the alternative pathway is independent of 
Cl, C2 and C4 and is initiated by polysaccharides from plant and 
bacterial cell walls and aggregated or complexed IgA. Factor B 
(synonyms C3 proactivator CC3 Pro A) and glycine rich 3 glycoprotein 
(GBG)) is the C2a counterpart and is^activated by a protein. Factor 
D, to give C3 Activator (C3A) which is capable of activating C3.
The reaction is then believed to proceed as in the classical
16
pathway. Although activation of the properdin pathway is said to 
be independant of C  components Cl, C2 and C4, it is known that if 
C3b is present it catalyses the activation of C3A. This positive 
feedback loop is modulated by the C3 inactivator KAF (conglutinogen- 
activating factor), which inactivates C3b. The two systems of C  
activation are clearly interrelated (Takada, Imamura and Takada, 
1979).
However C3 is activated, the sequence proceeds with release 
of C3a, an anaphylatoxin which can release histamine from mast cells 
and cause smooth musCle contraction, and from cleavage of C5 a 
similar small fragment C5a with histamine releasing activity and 
chemotactic properties for PMN leucocytes and monocytes. C5b forms 
a complex with C6 and Cl in the fluid phase and becomes bound to the 
cell membrane. Finally the terminal C  components C8 and C9 become 
bound and membrane damage with cell lysis results. C8 is believed 
to have a phospholipase-like activity and C9 is thought to enhance 
this activity.
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1.7. IMMPLICATIONS OF COMPLEMENT ACTIVATION IN CROHN’S DISEASE 
The presence of ICs in serum is implicated by fixation and 
activation of C . Sera that contain C '-fixing ICs will also fix C ' 
in vivo. This project was designed to show the extent of C  activity 
and detection of ICs in the serum of patients with CD. Ijn vivo C  
activation was examined by measuring total haemolytic complement 
levels, serum concentration of C  components C3 and C4 and by 
demonstrating C3 inactivation products. The presence of ICs was 
determined by a method of measuring anticomplementary activity (ACA) 
in patients' sera. Sera that showed evidence of containing ICs were 
additionally analysed by gel chromatography in an attempt to localise 
the ACA to a particular molecular weight range and to characterise 
the immunoglobulin content of the ICs.
CHAPTER 2 
MAT ERIALS AND METHODS
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2.1. MATERIALS
All chemicals and reagents were of analytical grade whenever 
available and unless otherwise stated, came from normal commercial 
sources, such as British Drug Houses, Poole, Dorset. (Appendix II) 
The following specific materials were also used:
Sheep red blood cells (SRBO) in Alsevers solution (Oxoid); 
Horse anti-SRBC antiserum (Wellcome);
Complement fixation test (CFT) buffer tablets (Oxoid);
0.04% ammonia solution;
Microtitre plates 8x12 U-shaped wells and lids (Titretek,
Flow Labs.);
Tulip loop microdilutors, 25 ul. (Titretek, Flow Labs.);
25 ul. pipettes (Titretek, Flow Labs.);
Freeze-dried guinea-pig complement (GP-C) (Wellcome); 
lonagar No. 2 (Oxoid);
Barbitone buffer, pH 8.6, ionic strength 0.1 (Appendix I); 
Antiserum to C3 and C4 (Hoechst);
Human serum standard (Hoechst);
Phosphate buffered saline (PBS) ph 7.35 ± O.OS' (Appendix I);
Coomassie Brilliant Blue (BDH) (Appendix I);
Hamilton microsyringe and adaptor (V.A. Howe);
Water baths at 56°C and 100°C;
Damp:chamber at 4°C;
Well cutter (Wellcome);
Glass slides, 10x16.5 cm.;






For all the methods described in this Chapter blood samples were 
treated in the following manner:
Venous blood was collected into plain bottles and allowed to 
clot at room temperature. Within 2 hours of collection the serum 
was spun off and dispensed into 0.5 ml. aliquots and frozen 
immediately at -70°C. A fresh aliquot was thawed once only prior 
to use for each test.
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2.2, METHODS
The methods of total haemolytic complement (Hudson and Hay, 1976) 
and anticomplementary activity (Johnson, Mowbray and Porter, 1975) 
assay and estimation of C3 and 04 concentrations (Mancini, 1965) are 
described as follows.
2,2.1, TOTAL HAEMOLYTIC COMPLEMENT
The principle of this assay is based on the fact that as 
complement (C) is added to antibody (Ab)-coated sheep red blood 
cells (SRBC), an increasing proportion of cells are lysed as shown 
in Figure 2.1. As it is difficult to determine the C  concentration 
that causes total lysis of the cells, the 50% lysis point is normally 
quoted, the CH^^.
The Von Krog% equation for the sigmoid dose-response curve of 
C'mediated cytolysis was arrived at empirically (Hudson and Hay, 1976) 
and in its basic form is:
X = k(^^l-y)^^* 
where x = amount of C  (ml. of undiluted serum) 
y = proportion of cells lysed 
k = 50% unit of C  
n is a constant
The CH^Q unit is an arbitrary unit dependent on SRBC and anti- 
SRBC concentration, buffering conditions of the medium, temperature, 
reaction time and concentration of calcium and magnesium ions.
Standard conditions must therefore be carefully controlled.
The method used was a titrimetric assay, similar to the method 







VOLUME C' ADDED (ARBITRARY UNITS)
FIGURE 21
LYSIS OF SHEEP RED BLOOD CELLS (SRBC) BY HORSE 




5 ml. of SRBC were washed 3 times in CFT buffer and suspended
in 15 ml. CFT buffer. 0.2 ml. of the suspension were added to 4.8
ml. 0.04% ammonia solution, this causing lysis of the cells. The
optical density was read at 541 nm. A 5% suspension of SRBC gives
an absorbance of 0.48-0.50 at 541 nm. The volume of the cells was
adjusted until this concentration was obtained, according to the
equation: volume = 15:.x OD .
 --  ml
.0.49
0.1 ml. horse anti-SRBC antiserum was added to 15 ml. CFT buffer 
and to this was added 15 ml. of 6% SRBC suspension. The final 
suspension was incubated at 37°C for 15 minutes, thus giving a 3% 
suspension of sensitized SRBC.
Dilutions of the patients serum from 1/2 to 1/4096 were made with 
25 yl. CFT buffer in the 12 horizontal wells of a microtitre plate 
using a tulip loop microdilutor. 25 ]il. 3% sensitized SRBC suspension
were titrated with the patients serum in a final volume of lOO yl. made 
up with CFT buffer. The haemolytic reaction was allowed to proceed 
for 60 minutes at 37°C with periodical shaking. The plates were left 
overnight at 4°c before reading. The unlysed cells settled out and 
formed a "button" in the bottom of the wells, the diameter of which 
dependson the volume of unlysed cells.
The titre of a patient's serum is the reciprocal of the highest 




On each plate one well was reserved for a control of 3 volumes 
of CFT buffer (75 yl.) and 1 volume sensitized SRBC (25 yl.).
2.2.2, ANTICOMPLEMENTARY ACTIVITY
The principle of this assay depends on the ability of immune 
complexes (IC) to bind C .  The patients serum is first incubated at 
56°C for 60 minutes to inactivate intrinsic C  already bound to ICs, 
if they are present. Guinea-pig complement (GP-C) is then added to 
detect the degree of C  binding in a system of sensitized SRBC. The 
titrimetric method used was based on the method described by 
Johnson, Mowbray and Porter (1975).
2.2.2.1. Method
A 3% suspension of sensitized SRBC was prepared as described 
in the method of CH^^ assay.
The GP-C was first titrated . with SRBC to give a concentration 
that would cause 100% lysis of SRBC before the patient's serum is 
added. The minimum haemolytic dose (MDH) of GP-C is the lowest 
dilution of GP-C that causes incomplete lysis of the SRBC. In the 
titration for ACA 2 MHD were used. After inactivation at 56°C for 
60 minutes the patients serum was diluted from 1/2 to 1/4096 as 
described for CH^^ assay. To this was added 25 yl. of 2 MHD of 
GP-C and 25 yl. of CFT buffer. The C  fixation reaction was allowed 
to take place at 4^C overnight.
25 yl. of sensitized SRBC were added and the haemolytic reaction 
allowed to proceed for 60 minutes at 37°c with periodical shaking.
The plates were left overnight at 4°C before reading. The unlysed 
cells settled out to form a "button" in the bottom of the wells, the 
the diameter of which depends on the volume of unlysed cells.
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The titre of a patient's serum is the reciprocal of the highest 
dilution of serum, previously incubated overnight with 2MHD of 
GP-C, giving 50% lysis of the sensitized SRBC e.g. ACA 16.
2.2.2.2. Controls
Included in each plate was a row of diluted (1/2-1/4096) heat
aggregated human immunoglobulin ((IgG), original concentration 0.85
mg/ml.
One well was reserved for a control containing no GP-C or 
patient's serum, but 2 additional volumes of CFT buffer (50 yl.).
A second well was reserved for a control containing GP-C but no 
patient's serum, and one additional volume of CFT buffer (25 yl.).
2,2.3. C3 AND C4 CONCENTRATIONS
C3 and C4 concentrations were determined by single radial 
immunodiffusion (Mancini et al, 1965) using agar plates prepared in 
the laboratory.
2.2.3,1. Method
5 ml. of 1% agar made up in barbitone buffer, pH 8.6, ionic 
strength 0.1 were melted in a water bath at 100°C and transferred to 
a water bath at 56°C to equilibrate for 30 minutes. Using a Hamilton 
microsyringe, 50 yl. of t±e appropriate antiserum (anti-C3 or anti-C4) 
was added to the molten agar and mixed by gentle rotation and
inversion of the bijoux bottle.
3 microscope slides were assembled in a U-shape on one glass 
plate. A second glass plate was placed on top and the 2 glass 
plates were held together with the microscope slides sandwiched in 
between, by 3 bulldog clips.
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Using a warmed Pasteur pipette, 5 ml. molten agar containing 
antiserum were introduced into the space formed by the microscope 
slides. The agar was allowed to solidify at room temperature, the 
plates being supported in vertical position. The top glass plate 
was carefully removed and the surface of the agar allowed to dry.
Using a template and gel cutter, 12 wells were cut in the gel.
Serum samples were diluted 1:1 with 0.9% saline and mixed 
gently. 1 yl. and 2 yl. of sample were applied to each well of the 
03 plate and the 04 plate, respectively. There were 9 samples and 
3 standards to each plate. Diffusion was allowed to take place 
over 72 hours in a damp chamber at 4°C.
Commercial human serum was used to make up 3 standards which 
were included in each plate.
The concentrations of the standards were:
03; 22, 44 and 88 mg%
04; 7.5, 15 and 50 mg%.
The plates were dehydrated by compression of the agar, covered 
with filter paper and absorbant tissue, with a 2 Kg. weight. After 
drying for 10 minutes at room temperature, the diffusion rings were 
visualised by staining in Coomassie Brilliant Blue for 5 minutes. 
Background stain was removed by washing in the destaining solution.
2 2Diameter CD ) was plotted against concentration.
CHAPTER ■ 3
COMPLEMENT AND IMMUNE COMPLEX STUDIES ON PATIENTS 
WITH CROHN'S DISEASE, ANKYLOSING SPONDYLITIS AND 
RHEUMATOID ARTHRITIS AND CONTROL SUBJECTS.
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3.1 INTRODUCTION
Many workers have reported evidence of immune complexes (IC) in 
the sera of patients with Crohn's disease (CD) using methods both 
based on the complement (C) system (Doe, Booth and Brown, 197.3; 
Hodgson, Potter and Jewell, 1977a) and on the inhibition of antibody 
(Ab)-dependent cytotoxic reactions (Jewell and MacLennan, 1973). In 
addition, measurement of serum levels of various components of the C  
system has revealed that they may be altered (Hodgson, Potter and 
Jewell, 1977b) or near normal levels (Teisberg and Baklien, 1974; 
and Teisberg and Gjone, 1975).
The involvement of ICs in the pathogenesis of rheumatoid arthritis 
(RA) and ankylosing spondylitis (AS) has been considered for many 
years (Norberg, 1974; Sturrock et al, 1975; Corrigal et al, 1978).
ICs were first described in the sera of some patients with RA by 
Kunkel et al (1961), and later in synovial fluids (SF) by Winchester, 
Agnello and Kunkel (1970). Again, ICs in SF have been identified by 
methods utilizing activation of the C  sequence (Zvaiffler, 1974;
Zubler et al, 1976) and by other methods (Barnett and MacLennan, 1972; 
Luthra et al, 1975). Alterations of C  levels in sera and SF have 
also been reported (Pekin and Zvaiffler, 1964; and Ruddy and Austen, 
1970).
As reported levels of ICs and C  components in sera from patients 
with CD appeared inconsistent, it was decided to investigate some of 
these parameters in sera of patients with CD at the Royal United 
Hospital, Bath. The sera from these patients were compared with those 
of age and sex-matched normal healthy subjects. In addition, some 
positive controls were included, namely SF from patients with RA and
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sera from patients with AS. A few SF from patients with non- 
rheumatoid arthridities (non-RA) were also included, i.e. 
monoarthritis, chondrocalcinosis and pseudo-arthritis.
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3.2 PATIENTS AND METHODS 
3.2*1 PATIENTS
The patients with CD were taken from in-patients and out­
patients at the Royal United Hospital, Bath. The overall group 
included 69 patients, age range 18-76 years, mean age 40 years.
33 patients with AS were taken from in-patients and out­
patients at the Royal National Hospital for Rheumatic Diseases,
Bath. Their age range was 24-64 years, mean age 43.5 years.
20 patients with RA were taken from in-patients and out-patients 
at the Royal National Hospital for Rheumatic Diseases, Bath. Their 
age range was 18-69 years, mean age 49 years. 6 patients with non- 
RA were also taken from this hospital. Their ages were not known.
The group of 54 control subjects included laboratory personnel 
and student volunteers. They were age and sex-matched with the patient, 
groups wherever possible, but the age range 18-60 years and mean 
age 27 years were lower than in the other groups.
As many sera and SF from patients and control subjects as possible 
were included in each series of determinations. Details of these are 
given in the results section.
3.2.2 METHODS
The methods of estimation of total haemolytic complement (THC), 
anti-complementary activity (ACA) and of C' components C3 and C4 have 
been described in Chapter II.
All blood samples were collected into plain bottles and allowed 
to clot at room temperature. Within two hours of collection the serum 
was centrifuged off, dispensed into 0.5 ml. aliquots and stored at -70°C.
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SF were collected into heparin tubes and centrifuged at 600g 
for 20 minutes. The supernatent was dispensed into 0.5 ml. aliquots 
and stored immediately at -70°C. Before use, SF were incubated at 37°C 
for 15 minutes with 0.5 mg./ml. of hyaluronidase. This process 
reduced the viscosity of the sample to that of serum.
3.2.3. STATISTICS
2The Kolmogorov-Smirnov (Seigel) two sample X test and students 
t-test were used to determine whether the CH^^ and ACA results and 
the C3 and C4 estimations, respectively, differed in the patient 
groups from the values obtained for the control subjects.
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3.3 RESULTS
The results of the various assays of sera and SF are presented 
as follows.
3.3.1. TOTAL HAEMOLYTIC COMPLEMENT
THC is expressed as a titre, this being the reciprocal of the 
highest dilution of sample giving 50% lysis of sensitized sheep 
erythrocytes, the CH^^. A low titre may indicate fixation of C  
by ICs.
Details of patients, age range, mean age and number of samples 
tested are given in Table 3.1.
Figure 3.1 illustrates the comparative percentage distribution 
of CH^^ titre. The normal range of CH^^ titre, as shown by 89% of 
control subjects, is considered to be between 16 and 128. 88% of sera
from patients with CD had activity within this range.
Statistical analysis of the cumulative percentage distribution
revealed no significant difference between CH^^ distribution in sera
2from control subjects and patients with CD (X = 3.264, p>0.1).
CH^g distribution was found to be significantly lower in sera
from patients with AS and SF from patients with RA when compared to
2 2 sera from control subjects (X = 74.41, p<0.001 and X = 13.7,
p<0.01, respectively).
No significant difference was found between CH^^ distribution 
in SF from patients with RA or non-RA (X = 2.219, p>0.2). However, 
the group of patients with non-RA was probably toosmall for tests of 
statistical significance.
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Crohn's Disease 60 116 18-76 40
Ankylosing
Spondylitis
33 33 26-64 43.5
Rheumatoid
Arthritis 20 20 18-69 49
Non-Rheumatoid
Arthritis 5 '5 NOT TOWN
Control Subjects 54 56 18-55 25.4
Table 3.1. ASSAY
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3.3.2. ANTICOMPLEMENTARY ACTIVITY
ACA is expressed as a titre, this being the reciprocal of the 
highest dilution of sample, previously incubated overnight with two 
minimum haemolytic doses (MHD) of guinea-pig C  (GP-C), at which 50% 
lysis of sensitized sheep erythrocytes occurs. If total haemolysis 
occurs, it can be inferred that are no ICs in the sample to cause 
fixation of endogenous C*. The higher the titre at which 50% lysis 
occurs, the higher the level of ICs in the sample. An extremely 
high content of ICs is indicated when no 50% end point can be discerned 
due to all the GP-C having been fixed.
Details of patients, age range, mean age and number of samples 
tested are given in Table 3.2.
Figure 3.2. illustrates the comparative percentage distribution 
of ACA titre.
96% of sera from control subjects had negative ACA and thus
showed no evidence of ICs. 68.8% of sera from patients with CD also
had negative ACA. Statistical analysis of the cumulative distributions
revealed that sera from patients with CD had significantly raised
2ACA when compared to sera from control subjects (X = 10.41, p<0.01).
All of the sera from patients with AS showed ACA. The cumulative 
distribution was significantly higher than that from the control sera 
(X̂  = 75.65, p<0.001).
45% of SF from patients with RA showed negative ACA, but the
cumulative distribution was significantly higher than that of sera
2from control subjects (X = 15.03, p<0.01).
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Crohn's Disease 55 107 18-76 39
Ankylosing
Spondylitis 33 34 26-64 43:5 :
Rheumatoid
Arthritis 20 20 18-69 49
Non-Rheumatoid
Arthritis 5 5 NOT K&[OWN
Control Subjects 50 52 18-55 25.3
Table 3.2. ACA ASSAY
Details of patients and control subjects
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PERCENTAGE DISTRIBUTION OF AC A  TITRE IN CONTROL SUBJECTS, 
(•-•). AND RûJIENTS WITH CROHNS DISEASE. (■-■) .RHEUMATOID 
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Statistical comparison of ACA in SF from patients with RA and
2non-RA revealed no significant difference (X =1.96, p>0.2). However, 
the group with non-RA was probably too small for tests of statistical 
significance.
3.3.3. C3 and C4 CONCENTRATIONS
C3 and C4 concentrations are expressed in mg% of serum or SF.
Details of patients, age range, mean age and number of samples 
tested with mean C3 and C4 concentrations ± 1 standard deviation (SD) 
are given in Table 3.3.
Comparative results of C3 determinations are given in Figure 3.3 
and of C4 determinations in Figure 3.4., with mean ± 1 SD.
Both mean C3 (98.51 ± 31.51 mg%) and mean C4 (35.44 ± 12.74 mg%) 
levels in sera of patients with CD were raised when compared to mean 
C3 (74.94 ± 19.95 mg%) and mean C4 (27.61 ± 10.34 mg%) levels 
measured in sera from control subjects (t = 5.27, p<0.005 and t = 4.07, 
p<0.005, respectively).
Conversely, mean C3 (54.3 ± 8.81 mg%) and mean C4 (19.32 ±
4.63 mg%) levels in sera from patients with AS and mean C3 (51.8 ± 
27.26 mg%) and mean C4 (10.74 ± 7.5 mg%) levels in SF from patients 
with RA were significantly lower than mean C3 and C4 levels in sera 
from control subjects (t = 5.60, p<0.0O5; t = 4.15, p<0.005 and t = 
4.26, p<0.005; t = 7.81, p<0.005, respectively).
No significant differences were found in C3 or C4 levels in SF 
from patients with RA or non-RA (t = 0.44, p>0.25 and t = 0.53, 
p>0.25). The group of patients with non-RA was probably too small 




1-4 f-4 m 10 10 in
in CO 10 CM in m O ' m
Ü *a rH CM CO X X X X O ' O
0 Q m 1-4 CM fH f—4
u +1 +\ 4-1 4-1 4-1 '4-1 4-1 4-1 4-1 4-1
C/i rH TT CM IT 10 IT f-4
c m IT m m CO X 10 IT O ' VO
td I—1
0) 00 m IT O ' 1—4 O CO CM IT X
s +1 G\ m in f-4 in f-4 IT f-4 X CM
(U
c? 1o CM in in
< M
Id O O 1—4 X O ' o z X X
c Q) IT IT 'T m in z CM CM







c CO 10 10 in X O ' O ' O o
Id k X in 10 lO VO VO
Id 1 1 1 1 1 1 1 1
0) CO CO O ' O ' CO CO O ' O '






A 0» in CO in o X m VO X m






0 o in in 00 in o X m VO n f-4




m IT ro TT m m IT m 'T





)4 O ' •H TJ Id
u C +J i4 CO CO
•H •H 0 •H f4 CO
+J CO (U CO f-4 4-> 4J 0) 4J f-4 +J
c CO 0 X Id •H fC •H 0 Ü
(U G Id «-4 73 )4 H V4 0)
•H x: o X C X : 1 .2 4J 1-1
■p 0 CO Q 0) 4J G +J c Xi
Id p •H c A Xi M 0 0 G































CROHN'S ANKYLOSING RHEUMATOID NONCONTROLS
DISEASE SPONDtUHS ARTHRITIS RHEUMATOID 
ARTHRITIS
FIGURE 3 3






CONTROLS CROHNS ANKYLDSING RHEUMATOID- NON
DISEASE SPCNDMJTB ARTHRmS RHEUMATOID
ARTHRITIS
FIGURE 3 4
DISTRIBUTION OF GONFLEMENT 04 LEVELS , WITH MEAN ± 1 
STANDARD DÉVIATTCN
40
There w^s a direct correlation between C3 and C4 levels in sera 
from patients with CD (Figure 3.5) (r = 0.514, p<0.001). This was not 
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3.4. DISCUSSION
Evidence of circulating ICs detected by the ACA assay was found 
in 32.2% of sera from patients with CD. This is in close agreement 
with Hodgson, Potter and Jewell (1977a), who found such evidence in 
27% of patients with CD using a similar ACA assay described by 
Johnson, Mowbray and Porter (1975). Johnson, Mowbray and Porter 
(1975) demonstrated the existence of circulating ICs in various 
pathological sera, not including CD, by ACA assay. They emphasised 
the importance of careful standardization of the assay, including 
standard storage methods, collection of samples, heat inactivation 
procedure and conditions of incubation with C '. This was confirmed 
by Neilsen and Svehag (1976).
In this study the experimental procedures and handling* of 
samples were standardized as far as possible.
Evidence presented by Hodgson, Potter and Jewell (1977a) using 
aggregates of immunoglobulin G(IgG) indicated that the ACA test 
detects small ICs, 11 Svedbergs (s) in size, whilst Clq precipitation 
detects larger complexes, over 20s in size. Using the Clq precipi- t. 
tation technique, they found that only 3 out 62 patients with CD showed 
evidence of large ICs. However, Doe, Booth and Brown (1973),using 
a different adaptation of the Clq precip’tation technique found that 
57% of patients with CD gave positive reactions. Clq is known to 
precipitate soluble ICs in agar gel (Agnello, Winchester and Kunkel, 
1970), but only if aggregates are over 19s in size. Hay et ^  (1976) 
devised a solid phase radio-assay for Clq precipitation and suggested 
that larger aggregates would be detected by these Clq precipitation 
methods because they had a higher avidity for Clq than small aggregates. 
Although the evidence remains controversial, it appears that Clq
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precipitation techniques detect ICs of a larger size whereas the ACA 
method may detect smaller ICs. With normal hepatic function in animal 
experiments (Mannik, Haakenstad and Arend, 1974) large ICs are rapidly 
cleared from the circulation by the reticulo-endothelial system (RES) 
whilst smaller ICs continue to circulate. This has been suggested 
to occur in humans (Hodgson, Potter and Jewell, 1977a) without liver 
disease and therefore a method of detection of smaller ICs may be of 
more use than one that detects larger ICs. Since ACA depends on 
activation of the whole C  sequence it should theoretically detect 
ICs which activate the C  system by both the alternative and classical 
pathways (Neilsen and Svehag, 1976) whereas Clq precipitation methods 
would only detect ICs which activate the C  sequence by the classical 
pathway via fixation of Clq. That is, only ICs containing IgG or IgM 
would be detected by Clq precipitation. As the inflamed mucosa in 
patients with CD contains increased numbers of Ig-producing cells 
(Baklien and Brandtzaeg, 1975) it seems likely that ICs may be 
formed in the mucosa itself (Hodgson, Potter and Jewell, 1977a) and 
may contain IgA.
Using the ACA method described, no evidence of ICs was found in 
sera from control subjects, apart from two sera which were strongly 
ACA positive. This activity may be due to misleading causes because 
both these samples were obtained on the same day in an extremely 
fatty state and on subsequent testing of second samples from these 
two individuals they proved to have negative ACA. It is possible that 
excessive fat content may have interfered with the ACA test. No 
other sera had such a fatty appearance. Apart from this discrepancy, 
all serum samples were collected and handled under identical condi­
tions, with the exception of sera from patients with AS which had 
been stored for slightly longer periods, up to 12 months compared to
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a maximum of 2 months for sera from control subjects and patients 
with CD and SF from patients with RA. Sera from patients with AS 
proved to have considerably greater ACA than other sera but not SF 
from patients with RA. lAll serum samples from patients with AS had 
some ACA, 44% being strongly positive indicating a high content of 
ICs. 55% of SF from patients with RA showed evidence of containing 
ICs. This is in agreement with previous experiments (Zvaiffler, 1 
1974; Barnett and MacLennan, 1972; Zubler et al, 1976) using various 
methods of IC detection. Of the five non-RA SF tested, only one 
showed any ACA. Despite the small size of this group, a lesser 
percentage showed evidence of ICs in the SF than did the group of 
patients with RA.
It could be inferred that sera from patients with AS showed 
greater evidence of ICs due to false positive results caused by 
aggregation of IgG during the longer period of storage. However, all 
samples were incubated for 60 minutes at 56°C prior to testing for 
ACA, and this treatment has been shown to reduce background ACA 
caused by aggregated IgG (Johnson, Mowbray and Porter, 1975; Neilsen 
and Svehag, 1976).
Other factors affecting ACA must be considered. Inhibitors of 
activated C  components e.g. Cl inhibitor (Cl-INH) and conglutinogen- 
activation factor (KAF) may contribute to giving f&lse positive ACA 
(Hodgson, Potter and Jewell, 1977a). Such inhibitors are destroyed by 
heating to 56°C for 60 minutes, so should not affect ACA under the 
conditions of these experiments.
When data from the CH^^ determinations were examined there was 
little apparent difference between patients with CD and control 
subjects. Statistical analysis using the Kolmogorov-Smirnov test 
confirmed no significant difference between the two groups.
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Reduced titre has been demonstrated in SF from patients
with RA (Pekin and ZVaiffler, 1964; Ruddy and Austen, 1970) and the 
results presented here are in agreement with that. Half of the 
samples tested had no detectable CH^^ titre. This indicates that C  
may be consumed by ICs. Similarly, 55% of sera from patients with 
AS showed no CH^^ titre indicating a high content of ICs. Statistical 
comparison with CH^^ titres in sera from control subjects showed 
CH^g titre to be significantly lower in sera from patients with AS 
and in SF from patients with RA. When distribution of CH^^ titre 
in SF from patients with RA was compared to that in SF from 6 
patients with non-RA the difference was not significant.
Estimation of CH^^ titre is an indirect test for the presence 
of ICs as a low titre may not necessarily be due to ICs and can be 
affected by many factors, such as diminished activity of one or more 
components of the C  system or an increased amount of inhibitor or 
inactivator. However, taken together with ACA titres of the same 
patient group conclusions can be drawn. As can be seen from the 
results, patient groups with high ACA also tend to have lower CH^^ 
distributions. When individual C  components C3 and C4 were 
measured a more striking difference between the groups emerged.
Sera from patients with AS had low CH^^ titres and also significantly 
reduced mean C3 and C4 concentrations when compared to control: 
values. C3 and C4 levels in SF from patients with RA were markedly 
reduced. Direct comparisons cannot be made between sera from control 
subjects and SF. Ruddy and Austen (1970) showed that C3 and C4 
concentrations in SF were significantly lower in subjects with 
seropositive RA than in subjecta with other degenerative joint 
diseases or seronegative RA. No significant difference was found 
here between C3 or C4 levels in SF from patients with RA or non-RA.
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This could be due to the fact that there were only 6 patients with 
non-RA and the patients with RA were not divided into seropositive 
and seronegative sub-groups.
In contrast, sera from patients with CD had comparatively normal 
CH^Q titres and raised ACA titres but the mean C3 and C4 concentrations 
were significantly elevated when compared to control values. Some 
workers have also found raised C3 and C4 levels in CD (Hodgson,
Potter and Jewell, 1977b) whereas others have reported them to be 
near normal (Teisberg and Baklien, 1974; Teisberg and Gjone, 1975).
It has been suggested that rises in C3 and C4 levels could be a 
result of non-specific inflammation (Hodgson, Potter and Jewell, 1977b) 
but it has been argued that since raised levels are also found in 
patients in remission (Ward and Eastwood, 1974) CV activation must be 
involved in the immunopathology of the disease. There was no 
significant difference between C3 and C4 levels in sera with positive 
or negative ACA titre (t = 0.854, p>0.25 and t = 0.534, p>0.25, 
respectively). C3 and C4 levels were significantly elevated in both
cases, suggesting this is not just an effect of inflammation but an
effect of an ongoing immui.ological process. Similar observations 
have been made with elevated C3 proactivator (C3 proA) levels in 
patients with CD in remission (Feinstein et 1976) suggesting 
involvement of the alternate pathway of C  activation. In the 
results presented here, since both C3 and C4 levels were raised the
classical pathway of C  activation is implicated.
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3.5 CONCLUSION
Many methods of IC detection are available, none of which is 
able to detect all ICs. Ig content, size and degree of latice 
formation in the complex are all important';. The method used, 
measurement of ACA, implicated ICs in all of the sera tested from 
patients with AS, 55% of SF from patients with RA and also in 
32.2% of sera from patients with CD. Control sera were negative 
in comparison. This method is considered to be a reliable and 
sensitive assay, providing conditions of experimentation and 
handling of samples are carefully standardized (Johnson, Mowbray 
and Porter, 1975; Neilsen and Svehag 1976) . It is possible that 
other methods may detect complexes of different sizes in pathological 
sera. CH^^ titre was normal in sera from patients with CD but . -I. J. 
individual C  components C3 and C4 were found to be raised. This 
could be due to reduced C3 metabolism or increased C  synthesis 
possibly as a feedback mechanism to compensate for increased C  
activation by ICs. In order to investigate this possibility,
C3 metabolism was examined by estimation of C3 inactivation products 
(C3i). This work is described in Chapter V.
CHAPTER -4 
COMPLEMENT AND IMMUNE COMPLEX STUDIES 
IN RELATION TO PARAMETERS OF DISEASE 
IN PATIENTS WITH CROHN'S DISEASE.
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4.1 INTRODUCTION
The work reported in Chapter III showed that 32.2% of sera 
from patients with Crohn's disease (CD) had evidence of circulating 
immune complexes (IC) as shown by assessment of anticomplementary 
activity (ACA). ACA was not found in an age and sex-matched 
population of control subjects. There was no difference in CH^^ 
levels between the two groups, but levels of complement XC') components 
C3 and C4 were both raised significantly in patients with CD.
Data obtained from work described in Chapter III was analysed 
in order to see if the variations observed could be ascribed to 
factors of the disease, namely disease activity, duration of disease 
and drug therapy. Attempts have been made previously by other 
workers to correlate such parameters with the presence of ICs in 
pathological sera. Early work concentrated on variations in C  
levels in sera from patients with ulcerative colitis (UC) (Thayer 
and Spiro, 1963; Fletcher, 1965) but later sera from patients with
CD were examined for correlations between circulating ICs and the
parameters mentioned above, (Jewell and MacLennan, 1973; Teisberg 
and Gjone, 1975; Hodgson, Potter and Jewell, 1977a and 1977b).
Analysis of CH^^ and ACA assay and C3 and C4 estimations in sera 
from patients with CD as described in Chapter III was carried out 
according to:




4.1.1 DURATION OF DISEASE
Variation in C  and ICs was examined according to the duration 
of disease process in the following categories:-
(i) less than 2 years;
(ii) 2-5 years;
(iii) 5-10 years;
(iv) over 10 years.
4.1.2 STEROID THERAPY
Corticosteroid therapy is a major therapeutic modality in the 
management of inflammatory and immunologically mediated diseases. In 
the cases of CD studied the most commonly used corticosteroid -
was prednisolone . The dose varied from 10 mg. three times
daily (t.d.s.) to little as 1 mg. per day. Generally patients 
were started on a high dose, to control an acute exacerbation, which
was gradually reduced over a few months as the symptoms subsided.
Azathioprine (AZA) is often used in conjunction with Pred 
therapy in CD. Again dosage is altered according to severity of
symptoms and in the patients of this study varied from 50 mg. t.d.s.
to 25 mg. daily.
Incidence of ICs and raised C  in sera of patients with CD was 
examined according to the following categories of steroid therapy.
(i) no steroids;
(ii) no steroids for at least 2 years ;
(iii) steroids.
A variety of other drugs are also used in the management of CD. 
including codeine phosphate , salazopyrine and isogel,
Their possible effects on the immune system will be discussed.
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4.1.3 DISEASE ACTIVITY
Disease activity was assessed by clinical, radiological and 
histological findings based on published criteria (Truelove and 
Witts, 1955; de Dombal et a^, 1974).
Results of IC detection and raised C  in the sera of patients 




4.2 PATIENTS AND METHODS
4.2.1 PATIENTS
Details of patients with CD and number of serum samples analysed 
for each parameter measured are given in Table 4.1.
4.2.2 METHODS
The methods of estimation of CH^_ and ACA titre and C3 and C450
concentrations are described in Chapter II.
All blood samples were collected into plain bottles and allowed 
to clot at room temperature. The serum was spun off within two 
hours of collection and dispensed into 0.5 ml. aliquots which were 
stored immediately at -70°C. Freezing and thawing of samples was 
avoided, a fresh aliquot being used for each test.
4.2,3 STATISTICS
2The Kolmogorov-Smirnov two sample X test (Seigel) and students 
t-test were used to determine whether the CH^^ and ACA results and 
the C3 and C4 estimations, respectively, differed in the various 
groups of patients with CD.
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The results of various assays on sera from patients with CD 
with different duration disease, steroid therapy and disease 
activity are presented as follows
4.3.1 DURATION OF DISEASE
The effect of duration of disease on C  and IC levels were 
studied in 82 patients with CD. The patients were divided into:.four 
categories of disease duration as described in the introduction.
4.3.1.1. Total Haemolytic Complement (THC)
THC has been defined in Chapter II.
Figure 4.1. illustrates the comparative percentage distribution 
of CH^Q titres within the four categories of duration of disease 
process.
Statistical analysis of the results revealed no 'difference in 
distribution of CH^^ titre between any of the groups of disease 
duration, (Table 4.2).
4.3.1.2. Anticomplementary Activity (ACA)
ACA has been defined in Chapter II.
Figure 4.2 illustrates the comparative percentage distribution 
of ACA titre within the four categories of duration of disease 
process.
Statistical analysis of the results revealed no relationship 










PERCENTAGE ŒSTRIBUTTON OF CHgo TITRE IN SERA FROM CRÜHN'S 
DISEASE PATIENTS WITH CURATION CF ŒSEASE
(i) LESS THAN 2 YEARS ( • - • )
(ii) 2 5 YEARS (■-■)
(iii) 5 10 YEARS (o-o)
(iv) MORE THAN 10 YEARS (o-o)
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Duration of Disease CHgo ACA
X2 P X2 P
<2 years-2-5 years 
<2 years-5-10 years 
<2 years->10 years 
2-5 years-5-10 years 


























Steroid Therapy CH50 ACA
X2 P X2 P
No steroids - 
no steroids<2 years
















Disease Activity CH50 ACA
X2 p X2 P
Active - quiescent 
disease
1.12 >0.1 1.08 >0.1
Table 4.2. Summary of Kolmogorv-Smirnov X test of significance
between CEgQ and ACA distribution in sera of 
patients with CD and duration of disease, steroid 






PERCENTAGE DIETREBUnON OFAC  ̂TITRE IN SERA FRCM CROHN’S 
□5EASE BMENTS WITH DURATION OF DISEASE
(i) LESS THAN 2 YEARS ( • - • )
(ii) 2-5 YEARS ("-=)
(iii) 5-10 YEARS (o - d )
(iv) MORE THAN 10 YEARS (o-o)
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4.3,1,3. C3 C4 Concentration
Complement components C3 and C4 are expressed in mg% of serum.
Figures 4.3 and 4.4 illustrate the comparative distributions 
with mean concentrations ±1 standard deviation (SD) of C3 and C4 
determinations, respectively.
Statistical analysis of mean C3 and C4 concentrations between 
the four groups of disease duration is given in Table 4.3.
As can be seen from Table 4.3., C3 and C4 concentrations were 
significantly raised in the group with less than (<),2 years disease 
duration when compared to concentrations in the group with 2-5 years 
disease duration. 03 and 04 concentrations were also significantly 
raised in the group with 5-10 years disease duration when compared 
to concentrations in the group with 2-5 years disease duration. 03 
concentrations in the group with 5-10 years disease duration were also 
significantly raised when compared to concentrations in the group with 
over (>) 10 years disease duration. No other significant differences 
were observed.
The highest mean 03 and 04 concentrations were found in the 
group with disease duration of 5-10 years and the lowest in the group 
with disease duration of 2-5 years.
Mean 03 and 04 concentrations in all groups were raised when 
compared to the control values quoted in Ohapter III, this being 
significant in all cases with the exception of the mean 04 concent­
ration in the group with 2-5 years disease duration which was raised 
when compared to the control mean, but not significantly so.
No direct relationship existed between duration of disease and 
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FIGURE A 3
ŒSTRIBUTIDN OF SERUM CCMFIEMENT ' 03 IN CROHN'S DISEASE 
PATIENTS WITH DURATICN OF DISEASE : ( i ) LESS THAN 2 YEARS
(ii) 2-5 YEARS
(iii) 5-10 YEARS 













(i) (ii) (iii) (iv)
FIGURE A A
DISTRIBUnON OF SERUM COMPLEMENT OA IN OROHN S DISEASE 
PAHENTS WITH DURATION OF DISEASE ( i ) LESS THAN 2 YEARS
Iii)2-5 YEARS
(iii)S-IO YEARS
(iv) MORE THA.N 10 YEARS
WITH MEAN ± 1 STANDARD DEVIATION
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Groups Compared t P t P
<2 years-2-5 years 
<2 years-5-10 years 
<2 years->10 years 
2-5 years-5-10 years 


























Table 4.3. Mean C3 and C4 concentrations in sera from 
patieïits with Crohn's disease and different 
duration of disease process with significance 
of difference of means between groups
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4.3.2 STEROID THERAPY
The effect of steroid therapy on C  and IC levels was studied 
in 62 patients with CD. The patients were divided into three 
categories of steroid therapy as described in the introduction.
4.3.2.1. Total Haemolytic Complement 
THC has been defined in Chapter II.
Figure 4.5. illustrates the comparative percentage distribution 
of CH^Q titres within the three categories of steroid therapy.
Statistical analysis of the results revealed no difference in 
distribution of CH^^ titre between any of the groups of steroid 
therapy (Table 4.2.).
4.3.2.2. Anti-complementary Activity 
ACA has been defined in Chapter II.
Figure 4.6 illustrates the comparative percentage distribution 
of ACA titres within the three categories of steroid therapy.
Statistical analysis of the results revealed no relationship 
between distribution of ACA titre and steroid therapy.(Table 4.2.).
4.3.2.3. C3 and C4 Concentration
Complement components C3 and C4 are expressed in mg% of serum.
Figures 4.7. and 4.8. illustrate the comparative distributions 
with mean ±1 SD of C3 and C4 determinations respectively.
Statistical analysis of mean C3 and C4 concentrations between 
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DISTRIBUTION OF SERUM CCMFIEMENT 03 IN CRCHNS DIŒASE 
PATIENTS TREATED WITH : (i) NO STEROIDS
(ii) NO STERŒCS FDR AT LEAST 2 YEARS
(iii) STEROIDS











[ÏSTRE3UHDN OF SERUM COMPLEMENT 06 IN CROHN S 
ŒSEASE PATIENTS TREATED WITH Ii) NO STERŒDS
(ii) NO STEROIDS FOR AT 
LEAST 2 YEARS
(iii) STEROIDS 
WITH MEAN ± 1 STANDÛRD DEVIATION
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Steroid Therapy C3 mg% ± 1 S.D. C4 mg% ± 1 S.D.
No steroids 95.77±30.72 32.68±14.65
No steroids<2 years 102.00±33.94 35.10±13.72
Steroids 99.08±33.23 36.74±12.21
Groups compared t P t P
No steroids -
No:. steroids<2 years 0.53 >0.25 0.47 >0.25
No steroids<2 years 
- steroids 0.35 >0.25 0.49 >0.25
Steroids - 
No steroids 0.47 >0.25 1.36 >0.1
Table 4.4. Mean C3 and C4 concentrations in sera from patients 
with Crohn's disease and steroid therapy, with 
significance of difference of means between groups
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No significant differences were found.
C3 and C4 concentrations were significantly raised in all groups 
when compared to control values quoted in Chapter III.
4.3.2.4. Other Drugs
A summary of other drugs used in the management of the patients 
with CD in this study is given in Table 4.5.
22 patients being treated with corticosteroids were also 
receiving AZA therapy, whereas, only 4 patients not on steroid therapy 
were being treated with AZA. Similar numbers of both patients who 
were on steroid therapy and those who were not, : ivere hlso being 
treated with the other drugs listed.
A similar percentage of both patients with active and quiescent 
disease were receiving steroid therapy, i.e. 64%. More patients with 
active disease were also on AZA therapy; 23/24 compared to 45/56 
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The effect of disease activity on C  and IC levels was studied 
in 76 patients with CD. The patients were divided into two 
categories of disease activity as described in the introduction.
4.3.3.1. Total Haemolytic Complement 
THC has been defined in Chapter II.
Figure 4.9. illustrates the comparative precentage distribution 
of CH^Q titre within the two categories of disease activity.
Statistical analysis of the results revealed no difference in 
distribution of CH^^ titre between the two groups of disease activity 
(Table 4.2.).
4.3.3.2. Anti-complementary Activity 
ACA has been defined in Chapter II.
Figure 4.10. illustrates the comparative percentage distribution 
of ACA titre within the two categories of disease activity.
Statistical analysis of the results revealed no relationship 
between distribution of ACA titre and disease activity (Table 4.2.).
4.3.3.3. C3 and C4 Concentrations
Complement components C3 and C4 are expressed in mg% of serum.
Figures 4.11. and 4,12, illustrate the comparative distributions 
with mean ±1 SD of C3 and C4 concentrations, respectively.
Statistical analysis of mean C3 and C4 concentrations between 
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ŒSTRELmON OF ÏRUM  COMPLEMENT 03 IN CROHN S OSEASE 
RATIENT5 WITH : ( i ) ACTIVE DISEASE
(ii) QUIESCENT DISEAS 





DISTRIBUTION OF SERUM COMPLEMENT 04 IN CROHN'S IISEASE 
PATIENTS WITH : (i) ACTIVE DISEASE
(ii) QUEISCENT DISEASE 
WITH MEAN ± 1 STANDARD DEVIATION
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Groups Compared t P t P
Active disease - 
Quiescent disease
1.10 >0.1 0.23 >0.25
Table 4.6. Mean C3 and C4 concentrations in sera from 
patients with Crohn's disease and disease 
activity, with significance of difference 
of means between groups
75
Mean C3 and C4 concentrations were higher in the group with 
active disease than in the group with quiescent disease, but this 
difference was not significant.
C3 and C4 concentrations were significantly raised in both 
groups when compared to control values quoted in Chapter III.
4.3.3.4. Serial Studies
Serial studies were possible in 13 patients with CD. The 
results of C  and IC estimations on the sera from patients in 
active and quiescent phases of the disease are shown in Table 4.7.
Only 2 patients (GB and F) showed an increase in CH^^ titre 
as the disease went into remission. In all other patients the..̂  
CH^g titre increased as the disease became active.
Only one patient ( F) showed a fall in ACA as the disease 
became quiescent. No relationship existed with change in disease 
activity and evidence of ICs.
C3 and C4 concentrations were higher in the active phase than 




CH50 ACA C3 C4 mg%
LB Active 32 16
Quiescent 32 2048
GB Active 32 -ve
Quiescent 128
Quiescent 256 32
MC Quiescent 16 32
Active 64 32
CD Active 64 -ve
Quiescent 32 -ve
Active -ve
TM . Quiescent 64 -ve 82 48
Active 64 -ve 75 42
VF Active 16 2 52
Quiescent 64 -ve 80 20.4
Active 16 -ve 118 24
HI Active 128 -ve 159 65
Quiescent 16 -ve 109 55.5
DP Quiescent 64 -ve 56 23.4
Active 128 -ve 96 40.4






ACA C3 C4 
mg%
CR Active 32 95 43
Quiescent 4 63 24
PT Active 64 -ve 81 22
Quiescent 32 -ve 94 28.2
■ BW Active 128 -ve 90 34
Quiescent 256 -ve 94 22.2
AW Active 16 -ve 92 34
Quiescent 128 -ve 89 32.6
GW Quiescent 167 49.6
Active 146 35.8
Table 4.7. (contd.) SERIAL STUDIES
CHgOf ACA, C3 and C4 estimations in 




32.2% of sera from patients with CD in this study were found 
to have evidence of circulating ICs. Serum components C3 and C4 
were found to be significantly raised in patients with CD when 
compared to concentrations in serum from control subjects. An 
attempt was made to correlate these findings with length of history 
of disease, steroid therapy and disease activity. Results of CH^^, 
ACA and C3 and C4 determinations have been analysed accordingly.
4.4.1. DURATION OF DISEASE
Lack of correlation between length of history of disease and 
evidence of circulating ICs in patients with CD has been noted by 
several workers using a variety of methods of IC detection (Jewell 
and MacLennan, 1973; Hodgson, Potter and Jewell, 1977a). The 
results presented here are consistent with this. Estimation of 
CH^Q showed no variation with length of disease process. ACA could 
not be correlated with duration of disease either. C3 and C4 
concentrations were all elevated when compared to control values 
but there was no relationship with length of history of disease.
It appears that immunological activityvdoes not vary with 
duration of CD. It is morellikely that there would be fluctuations 
of immunological activity in the chronic relapsing course of the 
disease which may be revealed by serial studies of disease activity 
(see later).
Long term drug therapy, commonly used in the managment of CD 
probably affects tests for immunological activity and may mask any 
clear relationships with duration of disease.
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4.4.2. STEROID THERAPY
Corticosteroids are often used to control acute exacerbations 
of CD as well as in the management of patients with chronic unremit­
ting disease.
Many clinical trials have.been designed to study the clinical 
features of the disease in response to treatment with corticosteroids 
alone or in conjunction with AZA. The many side effects of steroid 
therapy e.g. Cushing's syndrome, often necessitate its withdrawal 
and continuation of treatment with other drugs, such AZA, AZA 
belongs to the class of drugs known as immunosuppressants, commonly 
used in cancer chemotherapy and in the prevention of transplantation 
rejection. Recently the mode of action of AZA has been suggested 
to be immunostimulatory (Gyte and Willoughby, 1977), possibly due 
to reduced suppressor cell activity (Hodgson, et 1978). AZA also 
has many unwanted side effects, including nausea, vomiting and bone 
marrow depression.
Evidence of the efficacy of both corticosteroids and AZA therapy 
in CD is controversial. Early papers (Brooke, Hoffman and Swarbrick, 
1969; Avery-Jones, 1959; Drucker and Jeejeebhouy, 1970) reported AZA 
to be effective in the control of CD. Later this was disputed by 
Rhodes at al (1971). has been shown to be effective and the
control of symptoms induced can be maintained by switching to AZA 
therapy (Willoughby ^  1971; Rosenberg et al, 1976) . The use of
corticosteroids in the treatment of CD has recently been critisized 
(Smith at al, 1978).
Cortisone inhibits fibrous tissue formation and collagen 
deposition; whereas this does not happen with AZA (Drucker and 
Jeejeebhouy, 1970). Cortisone also causes lymphocytopenia, monocyto-
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penia, eosinopenia and neutrophilia (Fauci and Dale, 1974; Yu e^ al, 
1974) and decreased immunoglobulin production (Butler and Rossen,
1973). All sub-populations of lymphocytes are reduced vivo by 
corticosteroids, particularly the thymus-derived T-cells (Fauci and 
Dale, 1974; Yu et al, 1974; Hodgson ejt al, 1978). Despite these 
observations very little is known about how corticosteroids affect 
the immune response. In tests for Ab-Ag detection no. correlation 
has been found with steroid therapy: no correlation with inhibition
of ADCC (Jewell and MacLennan, 1973): ACA (Hodgson, Potter and
Jewell, 1977a) or Clq, C3, C4 or Factor B levels (Hodgson, Potter 
and Jewell, 1977b). CH^^ titre has been shown to rise during 
steroid and adrenocorticotrophic hormone (ACTH) therapy in UC • 
(Fletcher, 1965).
In the present study no difference in the levels of CH^^,
ACA, C3 and C4 was found in patients receiving steroid therapy and 
those who were not. The incidence of circulating ICs therefore does 
not appear to be affected by treatment with steroids.
Similar studies have been carried out on patients with UC by 
Neilsen et (1976), and they suggested that corticosteroids may 
affect formation of ICs by causing a decrease in release of Ag from 
inflamed gut resulting in a decrease of IC production and consequently 
a decrease in C  activation. No such evidence of this was found in 
the studies on patients with CD.
4.4.2.1 Other Drugs
Although the mainstay of drug therapy in CD is the use of 
corticosteroids and AZA, a variety of other drugs are used in 
conjunction with them. A summary of other drugs used in the 
management of the patients included in this study was given in j. / - 
Table 4.5.
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The effects of corticosteroids and AZA on immunological 
activity has already been discussed. Of the other drugs used in 
the management of CD, phenylbutazone being an anti-inflammatory agent, 
is the only one likely to have an effect on immunological activity.
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4.4.3. DISEASE ACTIVITY
Many workers have attempted to correlate disease activity with 
evidence of circulating ICs and have shown that ICs appear to 
increase with severity of disease (Jewell and MacLennan, 1973;
Teisberg and Gjone, 1975; Hodgson, Potter and Jewell, 1977a and 1977b). 
Most of these reports go into quite considerable clinical detail of 
parameters such as blood in faeces, number of bowel movements per 
day, signs of ulceration on sigmoidoscopy, cytological and biopsy 
findings, as described by de Dombal et al, (1974). Such detail was 
not possible in this study and patients were described as having 
either quiescent or active disease according to their clinical notes.
Although 32.2% of sera from patients with CD studied were 
found to have excess ACA there was no difference in this between 
patients with active or quiescent disease. This does not agree with 
the results reported by Hodgson, Potter and Jewell (1977a) who found 
an increase in ACA with increase in severity of disease. There was 
also no difference in distribution of CH^^ titre and disease activity 
in the present study.
Comparison of C  components C3 and C4 revealed that both were 
raised in cases of active disease, though not significantly.
Teisberg and Gjone (1975) found no disturbances of C3 or C4 
concentrations from normal and therefore no correlation with disease 
activity in CD. However, Hodgson, Potter and Jewell (1977b) found 
a tendency of C3 but not C4 levels to rise with increasing activity 
of disease. They found also raised Factor B levels in cases of 
active disease, thus implicating the alternative pathway of activation 
of the C  sequence in CD. Since both C3 and C4 levels were affected 
in this study the classical pathway is implicated.
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4.4.3,1. Serial Studies
Serial studies on 13 individual patients underlined the group 
statistics that no change in evidence of ICs could be detected in 
active or quiescent phases of the disease. C3 and C4 concentrations 
were higher in over half of the patients in the active phase.
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4.5 CONCLUSION
Although 32.2% of sera from patients with CD were found to have 
evidence of circulating ICs, this could not be correlated with i 
duration of disease, steroid therapy or disease activity. The three 
parameters of the disease mentioned above are interrelated. CD of 
long duration is punctuated by acute exacerbations which require 
intense drug therapy. Since there was no difference between 
patients with active or quiescent disease it can be concluded that 
the disease is characterised by an ongoing immunological process.
C3 and C4 concentrations were elevated in all the parameters 
studied when compared to control values, but did not differ within 
the parameters, except in the case of active disease, when C3 and 
C4 levels were elevated when compared to quiescent disease, but not 
significantly so.
CHAPTER 5 
EVIDENCE OF IN VIVO COMPLEMENT 




Previous chapters have dealt with the measurement of complement 
(C) activity and serum factors C3 and C4. This gives a static 
picture of the C  system in immune complex (IC) diseases. The 
serum concentration of a protein is influenced by a number of 
variables; plasma volume, extra-vascular distribution, fractional 
catabolic rate and rate of synthesis (Hodgson, Potter and Jewell, 
1977c). Studies of C3 metabolism give a more dynamic view of C  
activation. C3 plays a key role in the C  activation sequence being 
involved in both the classical and alternative pathways. Of the C ' 
components, C3 is the commonest C  protein, its serum concentration, 
being 1200 mg% (Mayer, 1973). The next commonest is 04, with a 
serum concentration of 200 mg%.
Metabolic studies, using radiolabelled 03, have shown that 
although 03 levels were normal or raised in patients with Orohn's 
disease (OD), the fractional catabolic rate and synthesis were 
increased (Hodgson, Potter and Jewell, 1977c). Such turnover 
studies are complicated, difficult and time consuming, requiring 
medical supervision. Hence they were not possible in the present 
study. ^
A dynamic view of 0' activation can also be gained by demon­
stration of 03 breakdown products in the sera of patients by 
immunoelectrophoresis (Laurell, 1965) . This method has been used by 
Teisberg and Gjone (1973) to demonstrate the presence of 03 
inactivation (03i) products in the sera of patients with various 
forms of liver disease. Similar determinations have been made 
using sera from patients with systemic lupus erythematosus (SLE) 
and with rheumatoid arthritis (RA) (Versey, 1973; Versey, Hobbs and
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Holt, 1973; Teisberg, 1975a) and from patients with inflammatory 
bowel disease (UC and CD) (Teisberg and Gjone, 1975; Neilseh et al 
1978) .
The principle of demonstration of C3 conversion in serum lies 
in the fact that during utilization of C ', C3 is split into two 
fragments, C3a and C3b (Mayer, 1973). C3b becomes bound and 
participates in the C  sequence after which it is further degraded 
to C3c and C3d. These fragments, C3b, C3c and C3d, retain some of 
the antigenic characteristics of the parent molecule and will 
cross-react with anti-C3 antiserum but have a higher electrophoretic 
mobility and so will migrate faster than the native C3. Separation 
of C3i products can therefore be achieved by electrophoresis in one 
direction. Quantitation and visualisation can then be secondarily 
achieved by electrophoresis into Ab-containing agarose in a second 
dimension, at right angles to the first, when immuno-precipitation 
peaks form. It is thought that the converted peaks contain C3b, C3c 
and negligible amounts of C3d (Teisberg, 1975b).
In this study serum and plasma from patients with CD and an age 
and sex-matched population of control subjects were tested for 
evidence of C3i products. As the use of plasma or serum in the 
detection of C3i products is controversial (Versey, 1973; Teisberg, 
1975b; Greenwood and Whittle, 1976; Pepys, 1977; Gumming and 
Verrier-Jones, 1977; Neilsen et al, 1978),it was initially decided 
to compare C3 conversion in plasma and serum from control subjects 
and patients with CD. In addition, C3 and C4 concentrations and ACA 
were measured in as many samples as possible, by the methods 
described in Chapter II. Nielsen et a^ (1978) showed a correlation 
between C3 activation and circulating ICs. The results' of
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detection of C3i products were examined for the existence of 
correlation with evidence of circulating ICs.
Evidence of circulating C3i products has been correlated with 
disease activity and prednisone medication in Goodpastures syndrome 
(Teisberg, 1975b) and disease activity in patients with CD (Teisberg 
and Gjone, 1975). The results presented here were examined for 
correlation with disease activity and steroid therapy.
88
5.2 PATIENTS, MATERIALS AND METHODS
5.2.1 PATIENTS
62 sérum samples and 20 plasma samples from 51 patients with 
CD and 17 serum samples and 10 plasma samples from 27 control 
subjects were tested for evidence of C3i products. The age range of 
patients with CD was 18-76 years, mean 41.3 years. Control subjects 
were laboratory personnel and student volunteers. Their age range 
was 19-58 years, mean 26.3 years.
5.2.2 MATERIALS
Electrophoresis tank with cooling plate, U77 (after Kohn); 
(Shandon Southern Instruments Ltd.)?
Power pack V500/150 (Shandon Southern Instruments Ltd.)p
Gel cutter and cutting blade (Shandon Southern Instruments Ltd.)?
Glass plates 5x5 cm. (Kodak);
Water baths at 100°C and 56°C;
Hamilton microsyringe and adaptor (V.A'. Howe) ;
Antiserum to C3 (Hoechst);
Agarose (BDH);
Barbitone buffer, pH 8.6, ionic strength 0.02 (Appendix I);
0.5 ml. serum/plasma sample;
Coomassie Brilliant Blue stain (BDH) (Appendix I);
Destaining solution (Appendix I).
5.2.3. METHODS
The method of two-dimensional Immunoelectrophoresis adopted was 
a modified version of the one described by Laurell (1968) and similar 
to the automated method of Versey (L973). It was performed as 
described overleaf.
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5.2.3.1. Preparation of agarose gel
The electrophoretic procedure takes place in two stages, first 
a simple electrophoresis in agarose gel, followed by a second at 
right angles to the first forcing separated serum proteins into 
agarose containing anti-C3 antiserum. Each stage requires slightly 
different preparation of the agarose gel.
Initially 4x3 ml. and 1x4 ml. of 1% agarose made up in barbitone 
buffer, pH 8.6, ionic stregnth 0.02, were melted in a water bath at 
100°C and transferred to a second water bath at 56°C to equilibrate 
for 30 minutes.
For the first stage of electrophoresis, the plate was prepared 
as follows; 4 ml. of molten agarose were poured onto a level 5x5 cm. 
glass plate and allowed to solidify. Four wells were cut in the 
gel, 0,5 cm, from one edge. The gel was divided into four equal 
segments each containing a well. The samples were applied to the 
wells.
For the second stage, the segments of agarose were transferred 
to separate 5x5 cm. glass plates and the remainder of each plate 
filled with 3 ml. molten agarose containing 20 ul. of anti-C3 anti­
serum, which had been added to the molten agarose after equilibra­
tion at 56°C for 30 minutes.
5.2.3.2, Preparation of the Electrophoresis Tank and Power Pack
The electrode vessels were filled with barbitone buffer, pH
8.6, ionic strength 0.02. The prepared agarose plate was placed 
on a central cooling plate and connected to the buffer solution 
on either side by two wicks.
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The power pack was used as a constant voltage supply. The 
apparatus was fitted with a circuit breaker which interupted the 
current if the lid should be removed during electrophoresis. A 
polarity changer was used to change the current direction between 
successive runs and so prevent the creation of concentration i 
gradients in the buffer compartments.
5.2.3.3. Serum Application and Electrophoresis
Serum samples were diluted 1:1 with saline and mixed gently.
2 yl. were added to the wells in the first agarose plate, using 
a Hamilton microsyringe.
Electrophoresis was carried out in the first dimension at 350 
volts for 45 minutes, causing separation of serum proteins towards 
the cathode.
Electrophoresis in the second dimension was performed at 
right angles to the first at 250 volts for 120 minutes. As the 
proteins migrated towards the cathode, C3 and its conversion products 
formed a precipitin line with the antiserum in the gel.
5.2.3.4. Staining
The precipitin peaks were visualised by staining with Coomassie 
Brilliant Blue. The agarose plate was first washed overnight in phos­
phate buffered saline (PBS) at 4°C to remove any unprecipitated 
proteins. Dehydration was effected by compression of the agarose, 
covered with filter paper and adsorbant tissue, with a 2 kg. weight. 
The agarose plate was stained in Coomassie Brilliant Blue for 5 
minutes. Background stain was removed by washing in the dye solvent 
(destainer) for 15 minutes.
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5.2.3.5. Controls
The position of the C3 peak was located by electrophoresis 
of commercial standard serum. The position of the C3i peak was 
located by electrophoresis of a serum sample, from a control subject, 
which had been left at room temperature for 7 days to allow natural 
conversion of C3.
The contuDols were run with each batch of test samples.
5.2.3.6. Blood Samples
Blood samples were collected from control subjects and patients 
with CD into plain bottles and allowed to clot at room temperature. 
Within 2 hours of collection the serum was spun off, dispensed into
0.5 mi. aliquots and stored immediately at -70°c.
For comparative experiments with EDTA plasma, blood samples 
were collected into EDTA tubes and centrifuged. The plasma was 
dispensed into 0.5 ml. aliquots and stored immediately at -70°C.
Freezing and thawing of samples was avoided, a fresh aliquot
being thawed once only prior to use.
5.2.4. C3 AND C4 DETERMINATIONS
C3 and C4 concentrations in samples tested for C3 conversion
were measured by the method of single radial immunodiffusion 
described in Chapter II.
5.2.5. ANTICOMPLEMENTARY ACTIVITY
ACA titre in samples tested for C3 conversion was estimated by 
the method described in Chapter II.
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5.2.6. DISEASE ACTIVITY
The patients with CD were divided into groups of active and
quiescent, disease according to the criteria described in Chapter 4.
5.2.7. STEROID THERAPY
The patients with CD were divided into 2 groups according to
whether they were receiving steroid therapy or not.
5.2.8. STATISTICS
2The X test was used to compare evidence of C3i products in 
plasma and serum; in control subjects and patients with CD; in 
patients with active and quiescent disease and in relation to 
steroid therapy.
The students t-test was used to determine whether C3 and C4 
concentrations differed in samples showing evidence of C3i products 
and in those that did not.
2The Kolmogorov-Smirnov X test (Seigel) was used to compare ACA 
in samples showing C3i products and in those that did not.
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5.3. RESULTS
The results of two-dimensional electrophoresis to demonstrate 
the presence of C3i products in sera and plasma samples from control 
sub]ects and patients with CD are presented as follows.
5.3.1. CONTROL SUBJECTS
Evidence of C3 conversion was not found in any of the serum 
or plasma samples from control subjects.
5.3.2. PATIENTS WITH CROHN'S DISEASE
Evidence of C3 conversion was found in 20/62 serum samples
and 7/20 plasma samples from patients with CD. There was no
significant difference between evidence of C3i products in serum 
2or plasma (X = 0.4, p>0.5).
Taken together, 32.9% of serum and plasma samples from
patients with CD showed evidence of C3 conversion. This was
2significantly different to the control group (X = 11.82, p<0.01).
5.3.3: C3 AND C4 CONCENTRATION
C3 and C4 concentration are expressed in mg% of serum or plasma.
Table 5.1. shows the mean C3 and C4 concentrations ± standard 
deviation (SD) in sera and plasma from control subjects and from 
patients with CD both showing C3i products and not showing C3i 
products.
Statistical analysis revealed that C3 levels were significantly 
raised in samples from patients with CD, whether they showed C3 
conversion or not (t = 4.94, p<0.005 and t = 5.38, p<0.005, 
respectively). C4 levels were significantly raised in samples from
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Patient Group C3 mg% ± 1 S.D. C4 mg% ± 1 S.D.
Control subj ects 68.62±14.98 (21*) 28.88±14.15 (21)
Patients with CD 
C3i +ve
102.32±30.26 (25) 30.34+ 9.33 (25)
Patients with CD 
C3i -ve
100.36i35.79 (55) 36.76±13.55 (53)
Difference from 
Control Mean t P t P
C3i +ve 4.94 <0.005 0.412 >0.25
C3i -ve 5.38 <0.005 2.41
. ..  .t
<0.01
Table 5.1. Mean C3 and C4 concentrations in control subjects 
and patients with Crohn's disease with and without 
evidence of C3 conversion, with significance of 
difference from control mean
* = Number of samples
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patients with CD who had no evidence of C3 conversion (t - 2.41, 
p<0.,01) . There was no difference in C4 levels in samples from 
patients wich CD who had circulating C3i products when compared 
to control values (t = 0.41, p>0.25).
When C3 levels were examined for variation in samples from 
patients with CD, no significant difference was found whether they 
showed C3 conversion or not (t = 0.26, p>0.25). In contrast, C4 
levels were significantly lower in samples from patients with CD 
showing C3 conversion (t = 2.44, p<0.01).
5.3.4. ANTICOMPLEMENTARY ACTIVITY
ACA has been defined in Chapter II.
12/26 samples from patients with CD that showed C3i products were 
found to have raised ACA (46%).
10/54 samples from patients with CD that showed no conversion 
of C3 were found to hâve raised ACA (18.5%).
Statistical analysis of the cumulative ACA distributions
2revealed this difference to be significant (X = 6.83, p<0.05).
5.3.5. DISEASE ACTIVITY
6/25 samples that showed C3i products were from patients in the 
active phase of the disease (24%).
14/52 samples that showed no evidence of C3 conversion were from 
patients in the active phase of the disease (26%).
Statistical analysis revealed no relationship between conversion
2of C3 and disease activity (X = 0.076, p>0.95).
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5.3.6 STEROID THERAPY
14/27 samples that showed 03 conversion were from patients 
receiving steroid therapy (51.8%).
36/55 samples that showed no evidence of C3 conversion were from 
patients receiving steroid therapy (65.5%).
Statistical analysis revealed no relationship between conversion
2of 03 and steroid therapy (X =1.4, p>0.5).
Results of ACA, disease activity and steroid therapy in 
relation to evidence of 03 conversion in samples from patients with 
CD are sumarised in Table 5,2.
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Parameter measured C3i +ve C3i -ve
ACA +ve 12* 10
ACA -ve 14 44
X2 = 6.83 p<0.05
Active Disease 6 14
Quiescent
Disease 19 38
X2 = 0.076 p>0.95
Steroid Therapy 14 36
No steroid 
Therapy 13 19
x2 = 1.4 p<0. 5
Table 5.2. Evidence of C3 conversion in relation to 
ACA, disease activity and steroid therapy
* = number of samples tested.
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5.4. DISCUSSION
In vivo activation of C  component. C3 as revealed by crossed 
Immunoelectrophoresis was found in 32.9% of serum and plasma samples 
from patients with CD. This percentage is lower than the figures of 
52.4% and 5.17% reported by Teisberg (1975b) and Teisberg and Gjone 
(1975), respectively. These workers studied C3 conversion in serum 
samples only. If the results presented here are considered 
separately, the percentage of serum samples showing C3 conversion is 
32.3%, whilst the percentage of plasma samples is 35%. However, 
there was no significant difference between the incidence of C3i 
products in serum or plasma.
Conversion of C3 was not found in any of the serum or plasma 
samples tested from control subjects. This indicates that vitro 
conversion of C3 does not occur: under the conditions of these experi­
ments. Demonstration of C3i products in sera and plasma from 
patients with CD can therefore, be taken as evidence of in vivo 
activation of the C  sequence.
There is much controversy as to whether serum or EDTA plasma 
should be used in experiments to demonstrate C3i products by immuno- 
electrophoresis. Many workers advocate using EDTA plasma (Versey," 
1973; Versey, Hobbs and Holt, 1973; Greenwood and Whittle, 1976; 
Neilsen et al, 1978). It is thought that the coagulation process 
accelerates vitro conversion of C3 (Krĵ ll, 1970) but this has 
been disputed (Teisberg, 1975b). Providing serum samples are 
stored at -75°C or used within 2 hours of collection, in vitro 
conversion of C3 does not occur to any appreciable extent (Laurell 
and Lundh, 1967; Teisberg and Gjone, 1973; Teisberg et al, 1973; 
Teisberg, 1975a). Laurell and Lundh (1967) did report traces of
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C3i products in sera from control subjects handled in the manner 
described. This was not substantiated in the results presented here. 
Serum and plasma samples used in these experiments were handled care­
fully, being stored at -70°C within 2 hours of collection and thawed 
once only prior to use. Because of the lability of C3 dm vitro 
a rapid method of high voltage Immunoelectrophoresis is desirable 
(Teisberg, 1975b), such as the one described here. A cooling plate 
was used during the electrophoretic procedure to help minimise in 
vitro conversion of C3. In addition, it has been suggested that 
plasma may be unreliable in immunoelectrophoresis, as fibrin may 
precipitate in calcium-containing gels (Teisberg, 1975a and 1975b).
This was unlikely to have affected experiments described here, as 
the barbitone buffer used to make up the agarose contained no calcium. 
More reliable results may be produced if EDTA is incorporated in the 
making up of the agarose when serum is to be used (Neilsen et al,
1978). However, the conditions of the experiments were considered 
to be reliable since no C3i products were detected in serum or plasma 
samples from control subjects.
C* components C3 and C4 were measured in most of the samples 
tested for C3i products. Versey (1973) had observed C3 and C4 
conversion in plasma from patients with SLE and RA with low levels 
of C3 in SLE and raised C3 levels in RA. Further studies reported 
by Versey, Hobbs and Holt (1973) included patients with a variety 
of mflammatory and neoplastic diseases. They found raised C3 and 
normal C4 levels in these patients but both groups gave evidence 
of conversion products. Similar measurements on sera from patients 
with SLE (Teisberg, 1975b) and with inflammatory bowel disease 
(Teisberg and Gjone, 1975) showed C3 conversion products in some patients
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with SLE with abnormally low levels of C3 and in patients with UC 
and CD with near normal C3 and C4 levels. The patients with CD in 
this study had raised levels of C3 when compared to control values 
whether C3 conversion was demonstrated or not. C4 levels were normal 
in patients showing C3 conversion and raised in patients with no 
evidence of C3 conversion. Raised serum C3 and the presence of C3i 
products reflects an increase in synthesis and catabolism i.e. an 
increased turnover rate (Hodgson, Potter and Jewell, 1977c). This 
indicates activation of the C  sequence possibly by ICs in the 
inflamed mucosa of the bowel (Ballard and Shiner, 1974). Levels of 
C4 within the normal range may indicate that the C  system is being 
activated via the alternative pathway, possibly by bacterial endo­
toxins or proteolytic enzymes in the damaged mucosa (Hodgson, Potter 
and Jewell, 1977c). However, the classical pathway may be involved 
since both C3 and C4 levels have been shown to be raised in patients 
with CD (Chapter III) and that there is a positive correlation 
between them, although raised C3 and C4 levels may be a reflection of 
the disease process causing an increase in the cells that manufacture 
these proteins. Activation of the C  system via the classical 
pathway would involve the consumption of C4 resulting in lowered 
concentrations of this protein. If the rate of synthesis is not 
increased as it is with C3 synthesis, then C4 levels would remain 
low. Kinetic studies such as those of Hodgson, Potter and Jewell 
(1977c) would reveal whether the catabolic rate and synthesis of 
C4 are altered in patients with CD.
Neilsen et a2 (1978) attempted to correlate the demonstration 
of C3i products with the presence of ICs, in the sera of patients with 
UC. They found evidence of C3i products in both IC positive and IC 
negative sera but conversion of C3 was significantly greater in the
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IC positive group. Similarly in the present study, evidence of ICs, 
as shown by measurement of ACA, was found in 46% of samples from 
patients with CD that showed C3 conversion and in 18.5% of samples 
which did not. The difference was significant, thus suggesting that 
ICs are the cause of C3 activation in patients with CD.
Teisberg and Gjone (1975) found a positive correlation between 
disease activity and evidence of C3i products in the serum of 
patients with CD. No such correlation was found heie. 24% of samples 
that had evidence of circulating C3i products and 26% of samples 
that showed no evidence of C3 conversion were from patients with 
active disease.
Fewer patients on steroid therapy had evidence of C3 activation 
(51.8%) than those who showed no evidence of C3 activation (65.5%) 
but the difference was not significant.
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5.5. CONCLUSION
C3i products were demonstrated in 32.9% of serum and plasma 
samples from patients with CD. This was taken to be evidence of 
in vivo activation of C3 and the C  system. Activation of the C  
system was thought to be caused by circulating ICs since their 
presence could be correlated to C3 activation.
No relationship was found between C3 activation and disease 
activity or steroid therapy.
C3 levels were raised whether C3 conversion was demonstrated 
or not. C4 levels were raised in samples showing no conversion 
of C3 but normal in samples showing C3 conversion. It was postulated 
that C3 and C4 metabolism and synthesis may be altered in patients 
with CD and that kinetic studies may reveal this.
CHAPTER 6
GEL FILTRATION STUDIES ON ANTICOMPLEMENTARY




The presence of circulating immune complexes (TC) in some of the 
patients with Crohn's disease (CD) has been indicated by the 
demonstration of higher than normal anticomplementary activity (ACA) 
in the sera of these patients (Chapter III).
Measurement of ACA detects ICs of less than 11s in size ' 
(Hodgson, Potter and Jewell, 1977a). In order to further charact­
erize ICs in the sera of patients with CD in terms of molecular 
weight (MW) and immunoglobulin (Ig) content, it was decided to 
fractionate ACA positive sera by column chromatography. This work 
is described in this chapter.
The material chosen for fractionation of serum was the mole­
cular sieve Sepharose 6B.
According to the theory of molecular sieving, proteins may be 
separated by virtue of their molecular dimensions. In a gel such 
as Sepharose 6B, an equilibrium is maintained between the liquid 
phase around the gel particles and the gel phase. Depending on the 
pore size of the gel, molecules may diffuse from the liquid phase 
to the gel phase. The rate at which a molecule moves down a column 
depends on the number of beads entered. Because the solute mole­
cules maintain a constant equilibrium between gel and liquid phase 
a sample moves down a column as a band. Large molecules, above the 
exclusion limits of the gel, will not enter the beads and so move 
with the advancing solute front while smaller molecules enter the 
beads and must traverse this space as well as the volume around the 
beads. All sizes of molecules above the exclusion limits of the gel 
appear in the void volume and are not separated from each other. 
Smaller molecules of related groups e.g. Igs will leave the column
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in order of decreasing size. MW is not the only factor governing 
the entry of molecules into a gel. Molecular shape and hydration 
are important. Hence proteins and carbohydrates have different 
exclusion limits in terms of MW.
Sepharose 6B has the following characteristics, which are 
necessary for the separation of IgG, IgA and IgM.
1. The approximate exclusion limit for proteins is 4x10^
5 5daltons. The MW of IgG is 1.6x10 ; IgA is 1.7x10 and
IgM is 9x10^, which are all below the exclusion limits of
Sepharose 6B.
2. The correct pore size. The proteins to be separated must 
be able to diffuse into the beads for molecular sieving to 
occur.
3. The gel is inert in relation to the material to be 
separated. Charged groups on the gel or affinity for the 
material will interfere with size separation.
4. The gel is finely dispersed, thus allowing rapid 
diffusion and effective separation, but not so fine as 
to slow the flow of solute molecules. Beads give good 
flow characteristics.
15 sera from 13 patients with CD included in the study 
described in Chapter III, which had positive ACA, were fractionated 
on a column of Sepharose 6B. Three pooled fractions were analysed 
for ACA, protein, IgG, IgA and IgM.
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6.2. PATIENTS, MATERIALS AND METHODS
6.2.1. PATIENTS
13 patients with CD, described in Chapter III, were included 
in this investigation. There were 8 males and 5 females, age 




100x25 cm column (Pharmacia);
10/150 buffer (Appendix I) ; 
combi coldrac 5201 cabinet (LKB);
Biocal chart recorder (LKB);
Bromma 7000 ultroac fraction collector (LKB);
UV spectrophotometer SP 600 (Unicam);
Diaflo PM 10 membrane and Amicon filter (Amicon).
6.2.2.2. Serum samples
Venous blood samples were collected into plain bottles and 
allowed to clot at room temperature. Within 2 hours of collection 
the serum was spun off, dispensed into 0.5 ml. aliquots and stored 
immediately at -70°C. 2 aliquots were required to give 1 ml. of 
sample which was diluted 1 in 3 with 10/150 buffer before 
application to the column,
6.2.2.3. Method
Sepharose 6B was obtained preswollen and a 100x2.5 cm. column 
poured. The column was equilibrated with 10/150 buffer and run 
at 8 ml./hour at 4°C. The void volume was estimated using blue 
dextran in 10/150 buffer.
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The sample was layered on to the column. 4 ml. fractions 
were dollected on an LKB ultrorac overnight. A 280 nm. profile was 
recorded on an LKB Biocal chart recorder at speed 10 ma./hour.
The column had previously been calibrated to give 3 major
fractions with MW ranges of >10^; 2x10^-10^? 5x10^-2x10^. When
all the protein had been eluted, the 4 ml. fractions were pooled
to give these 3 major fractions. The 3 major fractions were
concentrated using an Amicon filter and Diaflo PMIO membrane,
4 onominal exclusion weight 10 daltons, at O C. The first fraction 
(I) was concentrated from 16 ml. to 1 ml. and the second (II). 
and third (III) from 28 ml. and 24 ml., respectively to 2 ml.
The concentrates were divided into 0.5 ml. aliquots and snap frozen 
in liquid nitrogen until required for protein, Ig and ACA assay.
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6.2.3. FOLIN-CIOCALTEAU PROTEIN ESTIMATION
6.2.3.1. Materials
Solution A 5% copper sulphate;
B 10% sodium potassium tartrate;
C 2% sodium bicarbonate in 0.1 M sodium 
hydroxide;
D 1 volume Folin-Ciocalteau reagent +
2 volumes distilled water;
E 1 ml. A + 1ml. B + 8 ml. distilled water;
F 50 ml. C + 1 ml. E.
UV spectrophotometer SP 600 (Unicam);
Serum fractions I, II and III.
6.2.3.2. Serum fractions
Prior to protein estimation, fraction I was diluted 1 in 5; 
fraction II, 1 in 5 or 1 in 30 and fraction III, 1 in 100, 1 in 
200 or 1 in 600, depending on the protein content, with 10/150 
buffer.
6.2.3.3. Method
0.4 ml. of sample were added to 4 ml. solution F and 0.4 ml. 
of solution D. The solutions were whirlimixed together and the 
colour allowed to develop in the dark for 30 minutes at the ambient 
temperature. Each sample was estimated in duplicate. The optical 
density was read at 650 nm. against a reagent blank of 10/150 
buffer and solutions F and D.
A calibration curve was plotted from known concentrations of 
bovine serum albumin dissolved in 10/150 buffer and assayed 
following the above procedure.
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6.2.4. ESTIMATION OF IgG, IgA and IgM CONCENTRATION BY SINGLE 
RADIAL IMMUNODIFFUSION
6.2.4.1. Materials
Borate buffer, pH 8.6, ionic strength 0.05 (Appendix I);
I.D. agar tablets (Oxoid);
Antisera to IgG, IgA and IgM (Wellcome);
Ig standards for IgG, IgA and IgM (Hoechst);
Hamilton microsyringe and adaptor (V.A. Howe);
Water baths at 100°C and 56°C;
Phosphate buffered saline (PBS) pH 7.35±0.05 (Appendix I);
Damp chamber at 4°C;
Well cutter (Wellcome);
Coomassie Brilliant Blue stain (BDH) (Appendix I);
Destaining solution (Appendix I).
6.2.4.2. Serum fractions
With the exception of fraction III, serum fractions were diluted 
1 in 2 with PBS before application to the IgG plate. Fraction III 
was applied undiluted to the IgG plate as were all fractions to the 
IgA and IgM plates.
6.2.4.3. Method
5 ml. plates of 1% agar containing the appropriate concent­
ration of antiserum (IgG, 1.5%; IgA, 2.5%; IgM, 1.2%) were prepared, 
using the method described for measurement of C3 and C4 (Chapter II). 
The molten agar was allowed to equilibrate at 56°C for 30 minutes 
and the antiserum was then added. The agar was allowed to solidify 
and dry at room tempearture. Wells were cut in the agar using a gel 
cutter and template.
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2 ]il. of sample were applied to each well. There were 9 samples 
and 3 standards to each plate. The concentrations of the standards 
were:
IgG; 38, 90 and 185 mg%;
IgA; 90, 168 and 325 mg%;
IgM; 62, 163 and 258 mg%.
Diffusion was allowed to take place over 72 hours in a damp 
chamber at 4°C.
The plates were dehydrated and dried at room temperature before 
the diffusion rings were visualised by staining in Coomassie 
Brilliant Blue for 5 minutes. Background stain was removed by 
washing in the destaining solution.
2 2Diameter (D ) was plotted against concentration.
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$.2.5. ANTICOMPLEMENTARY ACTIVITY
The method of estimation of ACA has been described fully in 
Chapter II. The method was applied to determinations in the 3 
serum fractions obtained from Sepharose 6B fractionation of 15 
serum samples from 13 patients with CD.
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6.3. RESULTS
Results of protein, IgG, igA and IgM measurements and 
estimation of ACA titre in the 3 fraction pools obtained from 
fractionation of 15 serum samples from 13 patients with CD are 
shown in Table 6.1. The protein and Ig concentrations are 
expressed in mg% of concentrate.
9/15 Fraction I pools were found to contain IgG; 3/15 were 
found to contain IgA and one was found to contain IgM. ACA was 
detected in all fraction pools that contained IgG and in one that 
contained IgA but no IgG.
All 15 Fraction II pools were found to contain IgG and IgM 
and 6/15 were found to contain IgA. ACA was detected in 11/15 
fraction pools.
All 15 Fraction III pools were found to contain IgG and 13/15 
were found to contain IgA. IgM was detected in 2 fraction pools.
ACA was not detected in any of the fraction pools.
The highest protein concentration was found in Fraction III 
in all cases, the next highest in Fraction II and the lowest in 
Fraction I. IgG followed a similar distribution. IgA was almost 
equally distributed in Fraction II and III. IgM was predominantly 
found in Fraction II. In each of the 9 cases containing IgG in 
Fraction I the concentration of IgG represented a low precentage of 
the total IgG found in all 3 Fraction pools, i.e. 13.5%; 7.1%; 4.6%; 
3.6%; 1.3%; 23.2%; 2.3%; 2.3%; and 17%, respectively. In each of the 
3 cases containing IgA in Fraction I the concentration of IgA 
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Figure 6.1. shows the elution profile of a reference solution 
of IgG, IgM and albumin in 10/150 buffer. IgG and IgA were detected 
in the fraction pools as shown.
Figures 6.2. to 6.6. show elution profiles of sera from 5 
patients. The figures demonstrate the distribution of protein, IgG, 
IgA, IgM and ACA.
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Figure 6.1. Elution profile of a reference solution containing 
60 mg% IgM, 400 mg% IgG and 400 mg% human serum 
albumin in 10/150 mM buffer.

























Figure 6.2. Elution profile of serum from patient VF fractionated 
on Sepharose SB column.
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Figure 6,3. Elution Profile of serum from patient SA fractionated 
on Sepharose 6B column.





















Figure 6.4. Elution profile of serum from patient JR fractionated 
on Sepharose SB column.

















Figure 6.5. Elution profile of serum from patient MC fractionated 
on Sepharose 6B column.






















Figure 6.6. Elution profile of serum from patient DC fractionated 
on Sepharose 6B column.
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Gel filtration of ACA positive sera from patients with CD 
on a column of Sepharose 6B showed that the ACA was confined to 
Fraction pools I and II. The MW range of these 2 fractions, is >10 
6 5and 10 -2x10 daltons, respectively. This is above the MIV of 
monomeric IgG and IgA, but not IgM. Measurement of Ig classes by 
immunodiffusion revealed IgG and IgA in some of the Fraction I and 
II pools. IgG found in Fraction I was thought to be part of ICs 
rather than aggregates because the amount of IgG detected in 
these fractions was a small percentage of the total IgG measured 
in all 3 fraction pools. It has been shown that for IgG 
aggregates to fix C  they must be present in a high concentration 
(Neilsen and Svehag, 1976). IgG detected in Fraction II pools was 
probably in the form of dimers or small complexes. Again, the 
amount of IgG found in Fraction II represented a small percentage 
of the total. A high percentage of total IgA, however, was found 
in Fraction I and II pools and was probably in the form of 
aggregates or dimers, possibly as secretory IgA. It has been shown 
that serum IgA levels may be raised in patients with CD and that 
some of it may be secretory IgA (Deodhar et al, 1969; Perrett et al, 
1971).
As expected IgM was found in all 15 Fraction II pools. This is 
in accord with its MW which falls within the MW range of Fraction II, 
i.e. between 10̂ , and 2x10^. One Fraction I sample was found to 
contain IgM. It is possible that it could be present here as a 
component of a complex.
IgG was found in high concentration in all Fraction III pools 
where it must be presumed to be in its monomeric form. IgA was
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found in 13/15 Fraction III pools and would also be in its monomeric 
form. Two Fraction III samples also contained traces of IgM and it 
must be assumed that some degradation had taken place for IgM to be 
detected in a fraction of MW range lower than its own. ACA was not
detected in .any of the Fraction III pools.
Protein concentration was found to decrease through Fraction 
III to II to I. This distribution was similar to that of IgG.
Detection of ICs by ACA estimation depends on activation of 
the C  system. The C  system can be activated by complexes containing 
IgG via Clq fixation in the,Classical sequence and by complexes 
containing IgA via properdin in the alternative sequence.
It can be concluded from this work that ICs detected in the 
sera of patients with CD may contain IgG or IgA or possibly both.
IgM can also activate the C* system when complexed with Ag and it 
is possible that IgM complexes may also be involved in patients with
CD since one serum sample was found to have IgM in the high MW
Fraction I.
Serum fractionation by column chromatography has long been used 
to characterise complexes in the sera of patients with a variety of 
diseases. In 1967, Soothill and Hendrickse reported complexes 
containing C  component C3 in the high MW fraction after separation 
of sera from children with a nephrotic syndrome on a column of 
Sephadex G-̂ 200. Since the MW of C3 is 1.85x10^ daltons, it would 
be expected to appear in the same fraction as monomeric IgG or IgA. 
That it was found in a high MW fraction indicates that it was present 
in a complexed state.
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ICs have been detected in the serum of patients with other 
inflammatory diseases such as rheumatoid arthritis (RA), ankylosing 
spondylitis (AS) and systemic lupus erythematosus (SLE) by a variety 
of methods including the inhibition of antibody-dependent cytotoxic 
reactions (MacLennan, Loewi and Howard, 1969; Corrigal et al, 1978), 
platelet aggregation (Norberg, 1974) and inhibition of Fc rosette 
formation (Morito ^  al, 1976). Gel filtration of the sera in the 
afore-mentioned publications on columns of Sephadex G-200, Sephadex 
G-150 and Sepharose 6B and 4B showed that ICs were found in high 
MW fractions and that they contained IgG which was not normally 
found in these fractions. Plasma from patients with RA have been 
shown to contain IgG which on Sepharose 6B analysis was found to be 
in the fractions between the IgG and IgM markers (Pope £t al, 1974). 
ICs have been detected in the sera of patients with dermatitis 
herpetiformis (Mowbray et al, 1973).by methods of ACA titration and 
Clq precipitation. Subsequent fractionation of these sera revealed 
ACA in high MW fractions containing IgG.
Similar studies have been carried out on sera from patients with 
inflammatory bowel disease. Evidence of ICs in patients with CD 
and UC was indicated by the ability of their sera to inhibit anti­
body-dependent cytotoxic reactions (Jewell and MacLennan, 1973).
After fractionation on a column of Sepharose 6B, inhibitory activity 
was found in fractions with MW greater than that of IgG but lower : 
than that of IgM. Similar findings were reported by Henderson et a2 
(1976). In addition, Hodgson, Potter and Jewell (1977a) demonstrated 
the presence of ICs in the sera of patients with CD by ACA assay 
and on Sepharose 6b separation found peak ACA in high MW fractions 
containing IgG.
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The results reported in this chapter are consistent with the 
published results mentioned cibove, except that none of the authors 
described detection of IgA in high MW fractions. In the present 
study IgA was often found in fractions with a MW range above its
own monomeric MW. Although high MW IgA is likely to be in the
form of aggregates or secretory IgA, the possibility of IgA being 
involved in complexes cannot be discounted. It was concluded 
therefore, that ICs detected in the sera of patients with CD in this
study were found to contain high MW IgG and possibly IgA.
Other analytical methods are available for further character­
isation of ICs, such as sucrose density separation (Mowbray et al, 
1973; Norberg, 1974; Henderson et al, 1976), diethylaminoethyl- 
cellulose separation (MacLennan, Loewi and Howard, 1969; Henderson 
et al, 1976) and ultracentrifugation (Pope al, 1974; Morito
et al, 1976). Further information reguarding the nature of the ICs 
found in the sera of patients with CD in this study might be gained 
from the application of such analytical methods. Time did not 
allow this in the present study.
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6.5. CONCLUSION
ICs have been detected in 32.2% of sera from patients with 
CD by estimation of ACA. On fractionation of serum samples with 
evidence of ICs the ACA was found to be confined to two fraction 
pools of MW range >10^ and 2xlO^-io6 daltons. IgG and IgA were 
measured in these fractions by immunodiffusion. As the MW of IgG 
and IgA are lower than the MW range of these fractions it was 
concluded that the ICs were composed of IgG and possibly IgA 






Crohn's disease (CD) presents several features which suggest 
participation of the immune response in its pathogenesis and 
aetiology. One of these is the finding of immune complexes (IC) 
in the sera of some patients with CD (Jewell and MacLennan, 1973;
Doe, Booth and Brown, 1973; Hodgson, Potter and Jewell, 1977a; 
Hodgson, Potter and Jewell, 1977c; Fiasse, 1978).using a variety 
of methods. It has been suggested that ICs could be responsible 
for the extragastrointestinal manifestations often seen in this 
disease, i.e. uveitis, arthritis, vasculitis, liver disease and 
erythema nodosum (Hodgson, Potter and Jewell, 1977a). ICs are 
known to fix complement (C) (Mayer, 1973) and, as C  is one of 
the jnost important mediators of humoral immunity, the purpose of 
this thesis was to examine components of the C  system in relation 
to ICs in CD.
The activity of the C  system in sera of patients with CD was 
examined by CH^^ assay (Chapter III). CH^^ levels were found to be 
normal in contrast to CH^^ levels in rheumatoid arthritis (RA) and 
ankylosing spondylitis (AS) which were markedly reduced. RA and AS 
are thought to be IC-mediated diseasesL(Norberg, 1974; Sturrock e^ ̂  
1978) . The finding of nomal CH^^ levels in sera from patients with 
CD initially indicates that there is no apparent disturbance of C ' 
activity in this disease. However, estimation of CH^^ levels in 
sera depends on many factors. CH^^ assay is a measure of the 
activity of the whole C  sequence, from Cl to C9 (Takada, Imamura 
and Takada, 1979) via the classical pathway. It does not take 
into account individual C  components of the pathway. C  
consumption may be compensated for by increased synthesis of one 
or more C  components. C3 plays a key role in activation of the
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C ’ system by both the classical and alternative pathways. C4 is 
involved in the early stages of classical pathway activation. The 
serum concentrations of these two C  components were measured in 
patients with CD and were found to be significantly raised (Chapter 
III). Again, this contrasted to reduced levels found in sera from 
patients with AS and in synovial fluids from patients with RA.
Serum levels of C3 have been reported to be raised in patients with 
RA (Versey, 1973). Some workers have found raised serum C3 and C4 
concentrations in CD (Ward and Eastwood, 1974; Hodgson, Potter and 
Jewell, 1977b) whilst others have reported normal levels (Teisberg 
and Baklien, 1974; Teisberg and Gjone, 1975). Raised levels of 
serum C3 and C4 with normal CH^^ levels requires explanation.
Takada et al (1979) reported a positive correlation between CH^^ 
and C3 and a weak correlation between CH^^ and C4 in normal subjects. 
Serum concentration of a protein such as C3 and C4, reflects a 
balance between synthesis and catabolic rates, plasma volume and 
extravascular distribution (Hodgson, Potter and Jewell, 1977c), An 
increased serum concentration could be due to any of these factors. 
Kinetic studies of Hodgson, Potter and Jewell (1977c) have shown 
that both the fractional catabolic rate and rate of synthesis of 
C3 are increased in CD. This implies that C  activation is occuring, 
This will be discussed later (see page 135), but it does not dis­
count that a raised level may result from an imbalance between 
synthesis and catabolic rates. Finally the method of measurement 
of C3 and C4 levels may give rise to apparently high serum levels. 
The method of measurement of concentration by single radial 
immunodiffusion (Chapter II) depends on the rate at which a protein 
diffuses across a gel. Inactivation products of C3 and C4 are 
smaller molecules and would have a faster rate of diffusion in a
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gel thus giving an apparently higher serum concentration (Hodgson, 
Potter and Jewell, 1977b). This was thought to be unlikely, 
however, because no relationship was found between C3 levels and 
evidence of C3 inactivation (C3i) products (Chapter V). C3 levels 
were significantly raised whether C3i products could be demonstrated 
or not. C4i products were not measured but presuming C4 inactivation 
precedes C3 inactivation (classical pathway activation of C )  then 
C4 levels were less likely to be falsely elevated since C4 levels 
were actually no higher than control values in those sera that 
showed C3 conversion. A positive correlation was seen between C3 
and C4 concentrations indicating that activation was via the 
classical pathway.
Because ICs are known to activate the C  system, this fact 
can be utilized in their detection by anticomplementary activity 
assay. There are many methods of IC detection. No one method will 
detect all types of IC. ACA can be a useful method because it 
detects ICs that contain IgG and IgM by activation of C  via the 
classical pathway and possibly ICs that contain IgA, via the alter­
native pathway of C  activation (Neilsen and Svehag, 1976). ACA 
has been shown to detect ICs of small size, 11s, (Hodgson, Potter 
and Jewell, 1977a). In view of the fact that animal experiments 
have shown that large ICs are rapidly cleared from the circulation 
by the reticulo-endothelial system (Mannik, Haarkenstad and Arend, 
1974) a method of detecting small ICs is desirable. The presence 
of small ICs may indicate that larger complexes are also being 
formed. The method of ACA assay used is cheap, easy, sensitive, 
reproducible and requires very small amounts of serum (25 yl.).
False positive results due to aggregated IgG can be avoided by care­
ful handling of sera and heat inactivation procedures (Johnson,
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Mowbray and Porter, 1973; Neilsen and Svehag, 1976: Hodgson,
Potter and Jewell, 1977a).
Raised ACA found in 32.2% of sera from patients with CD (Chapter 
III) confirms the findings of Hodgson, Potter and Jewell (1977a) and 
is in agreement with the demonstration of ICs in the sera of a 
proportion of patients with CD by other methods (Doe, Booth and 
Brown, 1973; Jewell and MacLennan, 1973). Evidence of ICs was also 
found in all the sera tested from patients with AS and 55% of SF 
from patients with RA, using the method of ACA assay.
Gel filtration of ACA positive sera from patients with CD ( 
(Chapter VI) showed that ACA was confined to fraction pools of
molecular (MW) range 10-2x10^ daltons. This is greater than the M.W.
5 5of monomeric IgG (1.6x10 daltons) and IgA (1.7x10 ;daltons) but not
IgM (9x10^ daltons); IgG and IgA detected in these fractions were
thought to be part of ICs or aggregates. IgG was unlikely to be
aggregated since the IgG found in the high M.W. fraction was a
small percentage of the total and it has been shown that for
aggregates to bind C  they must be present in a high concentration
(Neilsen and Svehag, 1976). IgA detected in high M.W. fractions
may have been in the form of aggregates expecially when the
concentrations found in these fractions represented a high percentage
of the total IgA (Chapter VI, patient JR). It was concluded that
ACA found in serum of patients with CD was due to the presence of
ICs containing IgG and possibly IgA.
Estimation of CH^^, ACA, C3 and C4 levels in sera gives a 
static picture of the involvement of C  in the disease process of 
patients with CD. It was hoped to gain a more dynamic view of C
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activation from the demonstration of C3i products in sera of 
patients with CD. C3i products were demonstrated in 32.9% of 
samples. This percentage is lower than the figures of 52.4% and 
51.7% reported by Teisberg (1975b) and Teisberg and Gjone (1975), 
respectively. The discrepancy may be partly explained by the fact 
that there is much controversy over methodology. Since no evidence 
of C3 conversion was found in control subjects demonstration of C3i 
products in serum or plasma from patients with CD was taken es 
evidence of in vivo activation of the C  system. Activation of the 
C ' system was thought to be caused by circulating ICs because their 
presence, as detected by ACA assay, could be correlated to C3 
activation. Serum C3 levels were elevated whether C3i products 
were demonstrated or not, suggesting compensatory increase in 
synthesis. Kinetic studies of C3 metabolism in patients with CD 
(Hodgson, Potter and Jewell, 1977c) have shown that C3 synthesis 
and catabolism are increased. Serum C4 was found to be raised when 
no C3 activation was demonstrated but normal when C3i products were 
present. This suggests consumption of C4 during C  activation li 
which was not compensated for by increased synthesis. Kinetic 
studies of C4 metabolism might provide evidence to substantiate 
this hypothesis.
CD is a chronic condition following an unpredictable course of 
quiescent periods punctuated by acute exacerbations. Drug therapy 
is often required, mainly the use of corticosteroids usually 
prednisolone, and immunosuppressants, usually azathioprine (AZA). 
These types of drugs might be expected to have an effect on immuno­
logical activity, as might length of history of disease and 
disease activity. The relationship of these parameters to C  
and IC levels was examined in Chapter IV. No differences were
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found that could be attributed to length of disease process. Other 
workers have also failed to find any correlation with disease 
history (Jewell and MacLennan, 1973; Hodgson, Potter and Jewell,
1977a). It appears that once the disease is established the 
underlying immunological process is continuous. Steroid therapy 
alone or in conjuction with AZA does seem to be effective in the 
treatment of CD (Willoughby e^ al, 1971; Rosenberg al, 1976). 
although its use has recently been critisized.(Smith ^  al, 1978). 
However, no differences were seen in C  and IC determination whether 
the subjects were receiving steroid therapy or not. This confirms 
other reports of a lack of effect of steroid therapy on the presence 
of ICs (Jewell and MacLennan, 1973; Hodgson, Potter and Jewell, 1977a; 
Hodgson, Potter and Jewell, 1977b). The mechanism of action of 
steroids and immunosuppressants remains largely unknown. The 
beneficial effects of corticosteroids presumably include the 
anti-inflammatory actions, which may involve inhibiting the 
release of plasma kinins, a reduction of capilliary permeability 
and the ability to make cell lysosomes more resistant to agents that 
cause the release of lysosomal enzymes (Kraft and Kirsner, 1971).
The action of immunosuppressants, which may also apply to cortico­
steroids, may involve the reduction of the effects of antibody- 
antigen interactions at or near cell surfaces. The drugs may have 
a local effect on cell populations in the gut but no effect on 
circulating ICs.
Disease activity could not be correlated with the presence 
of ICs in the patients with CD studied although other authors have 
reported increases in circulating ICs and C  components with 
increase in severity of disease (Jewell and MacLennan, 1973;
Teisberg and Gjone, 1975; Hodgson, Potter and Jewell, 1977a;
137
Hodgson, Potter and Jewell, 1977b), C3 and C4 levels were higher 
in patients with active disease, but not significantly so. The 
distinction between active and quiescent disease was made subjectively 
according to clinical criteria. Other workers have employed more 
detailed discriminatory criteria for assessment of disease activity. 
This was not feasible under the conditions of this project. This 
could account for the lack of differences in immunological activity 
between patients in active and quiescent phases of the disease. 
However, the fact that ICs were detected and elevated serum levels 
of C3 and C4 were found in patients with quiescent disease lays 
emphasis on the suggestion that C  activation must be involved in the 
immunopathology of the disease (Ward and Eastwood, 1974).
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SUGGESTIONS FOR FUTURE WORK
This investigation has shown consistently elevated levels of C '
components 03 and 04 in the seirum of patients with OD, despite the
finding of activation of the O' system from AOA assay and the 
demonstration of circulating 03i products. From the experiments 
performed in this investigation it was concluded that AOA resulted 
from the fixation of O' by IgG-and possibly IgA-containing complexes 
with a MW of between >10^ and 2x10^ daltons. It would be of value
to pursue methods of 10 detection that are independent of O'
fixation. Preliminary attempts were made to do this by the. 
inhibition of Fc-rosette formation by sera from patients with OD.
The method has been described by Morito e^ a2 (1976) and shown to 
detect lOs in the sera of patients with SLE. Secondly, in order to 
elucidate the cause of raised O' levels it would be useful to 
examine the metabolism of 03 and 04 by kinetic studies.
Because the site of the pathological lesion is in the bowel, 
it may be more relevant to direct future investigations to examination 
of immunological parameters local to the site of gut injury, using 
biopsy and resected material. Immuno-fIncrescent studies have shown 
evidence of lOs in the bowel mucosa of patients with UO (Ballard 
and Shiner, 1974). Similar studies may provide information towards 
elucidation of the mechanisms of the aetiology of CD.
Because of the known modifying effects of prostaglandins on 
the immune system and because of the involvement of prostaglandins 
in UC it would be useful to investigate any role they may have in 
the. initiation or periodic resolution of CD through their 
inhibition of cytotoxic reactions. Knowledge of the modifying 
action of prostaglandins could lead to a rational approach to
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therapy in the disease by the use of agents which act in a similar 
(e.g. choleratoxin, ^-adrenergic agents, histamine, phosphodiesterase 
inhibitors) or opposite (a-adrenergic agents) fashion on cyclic 
AMP levels, as this agent is believed to function as a second 
messenger following prostaglandin stimulation. Obeying the dictât..s 
of the Yin Yang hypothesis it would be logical to examine whether 
agents which increase cyclic GMP (such as acetyl choline and 
carbamyl choline ) has an opposite influence on cytotoxic reactions 
to those which increase cyclic AMP levels.
Finally, investigations should concentrate on newly diagnosed 






Barbitone buffer, pH .8.6, ionic strength 0.1 
barbitone sodium 9 gm.
O.IN hydrochloric acid 65 ml. 
sodium azide 0.5 gm. 
distilled water 935 ml.
Phosphate buffered saline (PBS) pH 7.35 ± 0.05 
sodium chloride 32 gm. 
potassium chloride 0.8 gm. 
disodium hydrogen phosphate 5.1 gm. 
potassium dihydrogen phosphate 0.8 gm. 
distilled water 1 litre,
Coomassie Brilliant Blue stain
Coomassie Brilliant Blue 5 gm. 
methanol 450 ml. 
glacial acetic acid 10 ml. 
distilled water 450 ml.
Destaining solution 
methanol 450 ml. 
glacial acetic acid 10 ml. 
distilled water 450 ml,
Barbitone buffer, pH 8,6, ionic strength 0.1
Stock barbitone sodium 20.6 gm. 
barbitone 4.0 gm.
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sodium azide 1.0 gm. 
distilled water 1 litre.
working strength Stock diluted 1 in 5 with distilled water
to give ionic strength 0.02.
Borate buffer, pH 8.6, ionic strength 0.05 
boric acid 6.7 gm. 
disodium tetraborage 13.4 gm. 
sodium azide 0.5 gm. 
distilled water 1 litre.
10/150 buffer, pH 7.4.
150 mM sodium chloride in 10 mM phosphate
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1. Horse anti-sheep red blood cell haemolytic antiserum 
Cat. No. VD 16;
2. Freeze-dried guinea-pig complement 2 ml.
Cat. No. CT 01;
3. Well cutter;
4. Antisera to human IgG Cat. No. IP 26
. . ' IgA Cat. No. IP 25
IgM Cat. No. IP 27;
Oxoid Division of Oxo Ltd.,
London.
EC 4
1. Sheep red blood cells in Alsevers solution 
Cat. No. SR 53;
2. Complement fixation test buffer tablets ,
Cat. No. BR 16;
3. lonagar No. 2 
Cat. No. L 28;
4. I.D. agar tablets 





1. Antiserum to complement component C3 Cat. No. OTEA 04/05;
C4 Cat. No. OTNC 04/05;
2. Human standard serum 
Cat, No. ORDT 02/03;
3. Human standards for IgG Cat. No. OTRA 06/07;
IgA Cat. No. OTRB 06/07;
IgM Cat. No. OTRC 06/07.
Flow Laboratories Ltd, (Titretek),
Irvine,
Scotland.
1. Microtitre plates, 8x12 U-shaped wells Cat. No. 76-311-05;
+ lids Cat. No. 76-406-05;
+ sealers Cat. No. 76-401-05;
2. Tuilip loop microdilutors, 25 yl.
Cat. No. 76-742-02;
3. Disposable plastic pipettes, 25 yl 
Cat. No. 77-021-06.





2. 100x2.5 cm. column, SR 25/100 
Cat. No. 19-0880-01.
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2. Coomassie Brilliant Blue 
Cat. No. 15211 2A.
Shandon Southern Instruments Ltd.,
Camberley,
Surrey.
1. Electrophoresis tank with cooling plate, U77 
Cat. No. SAE 3225;
2. Power Pack, V500/150 
Cat. No. SAE 2770;
3. Horizontal table and spirit level;
4. Gel cutter and cutting blade.
V.A. Howe and Co. Ltd.,
London. SW6.








1. Amicon filter 
Cat. No. 202;
2. Diaflo membrane 
Cat. No. PM 10.
"C : Kodak U.K.,
Kirtoy,
Liverpool.
1. 5x5 cm. glass plates
LKB Biochrom Ltd.,
Cambridge.
1. Combi coldrac 5201
2. Biocal chart recorder
3. Bromma 7000 Ultrorac fraction.collector.
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